Transplant immunosuppression

By targeting specific gene expression in immune cells using therapeutic agents identified through advanced sequencing and transcriptomics, the method effectively prevents graft rejection and improves transplant survival rates.

WO2024246865A1PCT designated stage expired Publication Date: 2024-12-05UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/055359
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current immunosuppressive therapies for transplant patients are inadequate in addressing chronic rejection and graft fibrosis, leading to high rates of late graft loss and re-transplantation, as they fail to specifically target the complex immune cell interactions involved in acute cellular and antibody-mediated rejections.

Method used

The method involves administering therapeutic agents that target specific gene expression in immune cells, such as proteasomal components, immune synapse genes, chemokine genes, and growth factor genes, identified through scRNA sequencing and spatial transcriptomics, to reduce immune cell activation and prevent rejection in liver transplant patients.

Benefits of technology

This approach effectively reduces immune cell activation and prevents graft rejection by specifically targeting overexpressed genes in transplant patients, potentially improving graft survival and reducing the need for re-transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000036_0001
    Figure IMGF000036_0001
  • Figure 00000066_0000
    Figure 00000066_0000
  • Figure 00000066_0001
    Figure 00000066_0001
Patent Text Reader

Abstract

Methods are provided for treating acute graft rejection in allograft recipients. Druggable genes are identified, and therapeutic agents directed to lowering expression of those genes, including reducing activity of their gene products, are provided. Treatment may be personalized by including a step of identification of overexpressed genes in a patient, and tailoring treatment to the transcriptome of the patient's PBMC's or allograft by sequencing methods (bulk or single-cell) or spatial transcriptomics of a biopsy of the allograft.
Need to check novelty before this filing date? Find Prior Art

Description

TRANSPLANT IMMUNOSUPPRESSIONCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 505,814, filed June 2, 2023, the disclosure of which is hereby incorporated by reference in its entirety.REFERENCE TO A SEQUENCE LISTING

[0002] The Sequence Listing associated with this application is filed in electronic format and is hereby incorporated by reference into the specification in its entirety. The name of the XML file containing the Sequence Listing is 06527-2402775. xml. The size of the XML file is 18,257 bytes and the XML file was created on May 30, 2024.

[0003] Liver graft survival must exceed 50 years in children with rare end-stage liver diseases, most of whom receive liver transplants (LT) during early childhood and pre- teen years. However, up to a fifth of these children experience late graft loss and require re-transplantation within two decades, due to progressive immunologic injury and scarring. Progressive injury leads to loss of half of all organ transplants within 15 years among adult transplant recipients. Most adults are transplanted in their 40s and 50s, and must maintain a functioning graft for at least 25-30 years to achieve normal life expectancy. Also termed chronic rejection, scarring or graft fibrosis cannot be treated with current standard immunosuppressants, such as tacrolimus, antiproliferative drugs, and high-dose steroids. Predisposing events include T-cell- mediated acute cellular rejection (ACR) early after transplantation and antibody- mediated rejection which occurs later. This chronology and categorization limit our understanding of rejection mechanisms which may originate from many more functionally distinct immune cells in the mixed cellular infiltrate of the rejecting allograft. Examples include enhanced presentation of donor antigen by B-cells, and in some cases, the appearance of circulating donor-specific anti-HLA antibodies (DSA) during early LT rejection. Another example consists of T-cell transcripts and circulating DSA in varying combinations in late allograft biopsies with non-specific fibroinflammatory changes.

[0004] This process-driven categorization of rejection also translates into empiric drug selection, while ignoring specific targeting possible with some immunosuppressants.Antiproliferative drugs and high-dose steroids are added successively to tacrolimus, the mainstay of transplant immunosuppression, ending with T-cell or B-cell depletion for steroid-resistant rejection. Depleting agents can lead to abnormal cell proportions and enhanced alloreactivity among surviving cell populations, and loss of cancer immune surveillance, which can predispose to posttransplant lymphomas.

[0005] Discovery of useful therapeutics, including existing therapeutics that may be repurposed, to treat early (T-cell-mediated) ACR are desired.SUMMARY

[0006] To improve clinical practice, the molecular mechanisms which recruit several specialized immune cells and processes during early ACR were characterized in clinical patients. This effort revealed druggable targets for early intervention to prevent progressive injury and graft loss. scRNA sequencing and spatial transcriptomics were used to identify gene clusters and therapeutic targets for treating T-cell mediated rejection, e.g., acute cellular rejection (ACR) in transplants, e.g., liver transplants.

[0007] A method of treating acute graft rejection in a patient is provided, comprising, administering to the patient one or more therapeutic agents for lowering expression of a gene (including its corresponding protein) selected from one or more of a proteasomal component gene, an immune synapse gene, such as a CD74 gene, a CD3 complex gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or graft tissue of the patient.

[0008] A method of treating acute graft rejection in a patient is provided comprising, conducting single-cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of the patient and / or conducting a spatial transcriptomics analysis of a graft biopsy of the patient, and determining, as compared to a reference cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of a non-rejector or normal patient and / or a spatial transcriptomics analysis of a graft biopsy or normal tissue of a non-rejector patient, expression of one or more of a proteasomal component gene, an immune synapse gene, such as a CD74 gene, a CD3 complex gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, and where one or more of the proteasomal component gene, an immune synapse gene, a chemokinegene, a chemokine receptor gene, and / or a growth factor gene are overexpressed in the patient’s sample as compared to expression in the normal or non-rejector patient, administering to the patient one or more therapeutic agents for lowering expression of a gene selected from one or more of a proteasomal component gene, an immune synapse gene, such as a CD74 gene, a CD3 complex gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

[0009] The following numbered clauses outline various aspects and embodiments of the present invention.

[0010] Clause 1 . A method of treating acute graft rejection in a patient comprising, administering to the patient one or more therapeutic agents for lowering expression of a gene (including expression of its protein product) selected from one or more of a proteasomal component gene, an immune synapse gene, a CD3 complex gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

[0011] Clause 2. The method of clause 1 , wherein the gene is a proteasomal component gene.

[0012] Clause 3. The method of clause 1 , wherein the gene is PSMB9 or PSME1.

[0013] Clause 4. The method of clause 2 or 3, wherein the therapeutic agent is selected from bortezomib, carfilzomib, ixazomib, and an RNAi agent targeting a transcript of the proteasomal component gene.

[0014] Clause 5. The method of clause 1 , wherein the gene is a CD74 gene.

[0015] Clause 6. The method of clause 5, wherein the therapeutic agent isMilatuzumab, an RNAi reagent targeting a transcript of the CD74 gene.

[0016] Clause 7. The method of clause 1 , wherein the gene is a chemokine gene.

[0017] Clause 8. The method of clause 7, wherein the gene is CXCL10 or CXCL13.

[0018] Clause 9. The method of clause 7 or 8, wherein the therapeutic agent is selected from, atorvastatin, atropine, eldelumab, methylprednisolone, NI-0801 , oxaliplatin, regramostim, ritonavir, stavudine, testosterone, zidovudine, MDX-1100, and an RNAi agent targeting a transcript of the chemokine gene.

[0019] Clause 10. The method of clause 1 , wherein the gene is a VEGF gene.

[0020] Clause 11 . The method of clause 10, wherein the gene is VEGFA.

[0021] Clause 12. The method of clause 10 or 1 1 , wherein the therapeutic agent is selected from, bevacizumab, aflibercept, brolucizumab, ranibizumab, docetaxel, bevacizumab, oxaliplatin, pegaptanib, sorafenib, irinotecan, capecitabine, lenalidomide, OSI-632 (e.g., 3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1 - yl)butyl)ureido) isothiazole-4-carboxamide), bevasiranib, sunitinib, cisplatin, cilostazol, domatinostat, CDC-801 (e.g., 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(1 ,3- dioxoisoindolin-2-yl) propanamide), squalamine, risuteganib, fluorouracil, muparfostat, phenytoin, gentamicin, fenofibrate, conbercept, milatuzumab, MP-0250 (e.g., a VEGF / HGF-targeting DARPin), regorafenib, sildenafil, carboplatin, zaltrap, navicixizumab, elmiron, abicipar, celecoxib, leucovorin, enalapril, temozolomide, zoledronic, pemetrexed, cetuximab, fulvestrant, panitumumab, prednisone, IFNa2a, 5-fluorouracil, dalteparin, paclitaxel, gemcitabine, etoposide, lomustine, topotecan, olaparib, gefitinib, carmustine, erlotinib, thalidomide, atezolizumab, acid, vanucizumab, chelerythrine, faricimab, entrectinib, and an RNAi agent targeting a transcript of the chemokine gene.

[0022] Clause 13, the method of clause 1 , wherein the gene is CD3 and, optionally, the therapeutic agent is foralumab.

[0023] Clause 14. The method of any one of clauses 1 -13, wherein the graft is a liver allograft.

[0024] Clause 15. The method of any one of clauses 1 -14, wherein the therapeutic agent is an RNAi reagent or an antisense oligonucleotide.

[0025] Clause 16. The method of any one of clauses 1 -14, wherein the graft rejection is T-cell mediated.

[0026] Clause 17. The method of clause 1 , further comprising conducting single-cell or bulk sequencing of a peripheral blood mononuclear cell (PBMC) or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of the patient and / or conducting a spatial transcriptomics analysis of a graft biopsy of the patient, and determining, as compared to a reference cell or bulk sequencing of a PMBC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of a non-rejector or normal patient and / or a spatial transcriptomics analysis of a graft biopsy or normaltissue of a non-rejector patient, expression of one or more of a proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, and where one or more of the proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene are overexpressed in the patient’s sample as compared to expression in the normal or non-rejector patient, treating the patient with an amount of therapeutic agent for reducing expression of the overexpressed in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

[0027] Clause 18. A method of treating acute graft rejection in a patient comprising, conducting single-cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of the patient and / or conducting a spatial transcriptomics analysis of a graft biopsy of the patient, and determining, as compared to a reference cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of a non-rejector or normal patient and / or a spatial transcriptomics analysis of a graft biopsy or normal tissue of a non-rejector patient, expression of one or more of a proteasomal component gene, an immune synapse gene a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, and where one or more of the proteasomal component gene, an immune synapse gene a chemokine gene, a chemokine receptor gene, and / or a growth factor gene are overexpressed in the patient’s sample as compared to expression in the normal or non-rejector patient, administering to the patient one or more therapeutic agents for lowering expression of a gene selected from one or more of a proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.BRIEF DESCRIPTION OF THE DRAWINGS

[0028] FIG. 1 provides an exemplary cDNA sequence for PSMB9 (SEQ ID NO: 1 ).

[0029] FIG. 2 provides an exemplary cDNA sequence for PSME1 (SEQ ID NO: 2).

[0030] FIG. 3 provides an exemplary cDNA sequence for CD74 (SEQ ID NO: 3).

[0031] FIG. 4 provides an exemplary cDNA sequence for CXCL10 (SEQ ID NO: 4).

[0032] FIG. 5 provides an exemplary cDNA sequence for CXCL13 (SEQ ID NO: 5).

[0033] FIG. 6 provides an exemplary cDNA sequence for VEGFA (SEQ ID NO: 6).

[0034] FIG. 7. The effect of blocking the drug targets, CD74, CXCL10, VEGF and the proteasomal genes such as PSMB9 (upper panel), and CXCL13 (lower panel) with blocking antibodies on immune responses of human peripheral blood mononuclear cells (PBMC). The response was presentation of alloantigen by HLA-mismatched B- cells, and the expression of IL-6 in B-cells, CD154 in B-cells and the combination of IFN-gamma and CD154 in T-cells in responder PBMC which have been stimulated with HLA-mismatched PBMC. The respective blocking agents are anti-CD74 (Milatuzumab), anti-CXCL10 (edelimumab), anti-VEGFA (bevacizumab), bortezomib, and anti-CXCL13. In each bar diagram, the black bar represents the mean + / -SEM frequency of B- cells from healthy controls, incubated with HLA-mismatched antigen in three replicates. From left to right, bar diagrams show effect of this blockade on the frequency of a) B-cells that present alloantigen, b) allospecific IL6+B-cells, c) allospecific CD154+B-cells, d) allospecific CD74+B-cells, and e) allospecific IFNy+CD154+CD8 cells. These novel targets were identified with ST.

[0035] FIG. 8. L to R. Bortezomib suppresses donor antigen presentation in B-cells, donor-specific effector B-cells expressing IL-6, CD154 and CD74), and donor-specific effector CD8 cells that express IFNyandCD154. Three rejectors were tested.

[0036] FIG. 9. Role of memory T-cells and cytotoxicity in transplant rejection: The images below localize memory markers, MK167, ITGAE, CD69, and the cytotoxicity marker, GZMB (see inset in the image on the left) with fluorescent in situ hybridization to the various cells (see color legend) in two liver biopsies. The normal liver biopsy on the left which has no transplant rejection shows a portal region with cholangiocytes and portal and periportal liver sinusoidal endothelial cells eefte-(LSEC) which contains inflammatory cells (T-cells, NK cells, B-cells and macrophages). The liver biopsy on the right is from a transplant recipient experiencing acute cellular rejection which is mediated by cytotoxic T-cells (image in the middle). These T-cells have a predominantly memory phenotype. These T-cells also express the cytotoxic molecule GZMB. Images were obtained with the CosMx spatial molecular imaging system (Nanostring) which performs second generation spatial transcriptomics. Geneexpression is measured as counts of genes or as counts of cells that express a gene of interest.

[0037] FIG. 10. Chemokine-rich transplant rejection and donor-specific antibody. Images below show normal liver (left panel), liver with Transplant rejection (middle panel), and color legend for cells (right panel). Each image represents a 0.25„mm x 0.25 mm area? and contains a portal region which characteristically contain cholangiocytes (bile duct epithelial cells-red). The images localize the chemokines CXCL10 and CXCL13 to the portal and periportal regions of a liver transplant biopsy (red and light blue dots, respectively). These genes are overexpressed in liver with transplant rejection compared with normal liver. This biopsy was obtained from a recipient who also demonstrated circulating donor-specific anti-HLA antibodies (DSA). DSA mediate antibody- and complement-mediated damage to the transplanted organ. However, antibody-mediated damage is not easy to visualize by routine histologic staining with hemotoxylin-eosin in transplanted organs. Because of this limitation, antibody-mediated rejection is a diagnosis that is arrived at when T-cell-inhibiting or T-cell depleting strategies to treat T-cell mediated rejection fail to resolve ongoing injury to the organ. CXCL10 also known as IFN-gamma-inducible protein (IP10) is one of the three pro-inflammatory chemokines, CXCL9, CXCL10, and CXCL1 1. It is produced by many cells in response to IFN gamma induced stimulation, and binds to its receptor / ligand, CXCR3. It causes chemotaxis (movement and migration) of T- and B-cells and many other cells to sites of injury. CXCL13 or B-lymphocyte chemoattractant facilitates movement of B-cells to germinal centers to facilitate antibody production.

[0038] FIG. 11. CD74 target and Transplant rejection. Images below show normal liver (left panel), liver with Transplant rejection (middle panel), and color legend for cells (right panel). Each image represents a 0.25 mm x 0.25 mm area and contains a portal region which characteristically contain cholangiocytes (bile duct epithelial cells- red). The images localize the genes CD74 (green dots), which promotes presentation of antigen via the MHC class II pathway, HLA-DRA (blue dots), a major histocompatibility class II gene, and LTB or lymphotoxin B (red dots). These genes participate in immune synapse formation and are overexpressed in liver with transplant rejection compared with normal liver. The immune synapse connects two cells to each other and serves as a point of cell-cell contact. The immune synapse is essential for the initiation and amplification of the immune response. The inset on the rightmagnifies three types of cell-cell contact: 1 ) between endothelial cells (purple), inflammatory macrophages (bright green) and T cells (dull orange). T cells are known to recognize foreign antigen presented by the other two cells. 2) between T cells and inflammatory macrophages. 3) between T-cells, inflammatory macrophages, and B cells (pink). B cells are known to present antigen. The immune synapse genes CD74 which can serve as a novel drug target has a dense expression pattern showing that it is upregulated during rejection.

[0039] FIG. 12. Vascular endothelial growth factors and Transplant Rejection. Images below show normal liver (left panel), liver with Transplant rejection (middle panel), and color legend for cells (right panel). Each image represents a 0.25mm x 0.25 mm area and contains a portal region which characteristically contain cholangiocytes (bile duct epithelial cells-red). Also shown in the expression of the vascular endothelial growth factors VEGFA (green dots), VEGFB (blue dots), and VEGFC (red dots). These molecules are overexpressed in Liver with transplant rejection compared with normal liver.DETAILED DESCRIPTION

[0040] Other than in the operating examples, or where otherwise indicated, the use of numerical values in the various ranges specified in this application are stated as approximations as though the minimum and maximum values within the stated ranges are both preceded by the word “about”. In this manner, slight variations above and below the stated ranges can be used to achieve substantially the same results as values within the ranges. Also, unless indicated otherwise, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values. Further, as used herein, all numbers expressing dimensions, physical characteristics, processing parameters, quantities of ingredients, reaction conditions, and the like, used in the specification and claims are to be understood as being modified in all instances by the term “about”. Moreover, unless otherwise specified, all ranges disclosed herein are to be understood to encompass the beginning and ending range values and any and all subranges subsumed therein. For example, a stated range of “1 to 10” should be considered to include any and all subranges between (and inclusive of) the minimum value of 1 and the maximum value of 10; that is, all subranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less, e.g., 1 to 3.3, 4.7 to 7.5, 5.5 to 10, and the like.

[0041] As used herein “a” and “an” refer to one or more. The term “comprising” is open- ended and may be synonymous with “including”, “containing”, or “characterized by”. The term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.

[0042] As used herein, spatial or directional terms, such as “left”, “right”, “inner”, “outer”, “above”, “below”, “over”, “under”, and the like, relate to the invention as it is shown in the drawing figures are provided solely for ease of description and illustration, and do not imply directionality, unless specifically required for operation of the described aspect of the invention. It is to be understood that the invention can assume various alternative orientations and, accordingly, such terms are not to be considered as limiting.

[0043] As used herein, a “patient” or “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, a horse, and a whale), or a bird (e.g., a duck or a goose).

[0044] As used herein, the terms “treating”, or “treatment” refer to a beneficial or desired result, such as improving one of more, or symptoms of a disease. The terms “treating” or “treatment” also include, but are not limited to, alleviation or amelioration of one or more symptoms of graft rejection described herein. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment.

[0045] By “lower” in the context of a disease marker or symptom is meant a clinically- relevant and / or a statistically significant decrease in such level. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40%, or more, down to a level accepted as within the range of normal for an individual without such a disorder. In certain aspects, the decrease is down to a level accepted as within the range of normal for an individual without such disorder which can also be referred to as a normalization of a level. In certain aspects, the reduction is the normalization of the level of a sign or symptom of a disease, a reduction in the difference between the subject level of a sign of the disease and the normal level of the sign for the disease (e.g., to the upper level of normal when the value for the subject must be decreasedto reach a normal value, and to the lower level of normal when the value for the subject must be increased to reach a normal level).

[0046] “Therapeutically effective amount” or an “amount effective” as used herein, is intended to include the amount of a therapeutic agent as described herein that, when administered to a subject having a disease, is sufficient to effect treatment of the disease (e.g., by diminishing, ameliorating or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the nature of the injury and its causes, how the therapeutic agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated. A “therapeutically-effective amount” also includes an amount of a therapeutic agent that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment.

[0047] A "therapeutically effective amount" refers to an amount of a drug product or active agent effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. An “amount effective” for treatment of a condition is an amount of an active agent or dosage form, such as a single dose or multiple doses, effective to achieve a determinable end-point. The “amount effective” is preferably safe - at least to the extent the benefits of treatment outweighs the detriments, and / or the detriments are acceptable to one of ordinary skill and / or to an appropriate regulatory agency, such as the U.S. Food and Drug Administration. A therapeutically effective amount of an active agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the active agent to elicit a desired response in the individual. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount may be less than the therapeutically effective amount.

[0048] Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the composition may be administered continuously or in a pulsed fashion with doses or partial doses being administered at regular intervals, for example, every 10, 15, 20, 30, 45, 60, 90, or 120 minutes, every 2 through 12 hours daily, or every other day, etc.,be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. In some instances, it may be especially advantageous to formulate compositions, such as parenteral or inhaled compositions, in dosage unit form for ease of administration and uniformity of dosage. The specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.An “effective amount” or “amount effective” to achieve a desirable therapeutic, pharmacological, medicinal, or physiological effect is any amount that achieves the stated purpose, for example, an amount of an active agent described herein effective to reduce ACR or graft rejection in a transplant patient. Based on the teachings provided herein, one of ordinary skill can readily ascertain effective amounts of the elements of the described dosage form and produce a safe and effective dosage form and drug product. Because the nature of the active agents described herein varies greatly, and many are repurposed from other uses, a person of ordinary skill would know much about the therapeutic window of each drug, understanding bioavailability, toxic levels, effective targeting levels, etc. and can readily ascertain efficacy of any given dose by monitoring graft rejection parameters, such as transcriptome profiles in PBMC’s or graft biopsies, or determining organ function by suitable clinical biomarkers in the patient. PBMC populations may be refined to, CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cell populations. Examples of an effective amount of an active agent compounded in a delivery vehicle includes from 100 pg per ml (picograms per milliliter) to 1 mg / ml (milligrams per milliliter) of solution, including any increment therebetween, such as from 1 ng / ml (nanogram / milliliter) to 1 mg / ml or from 1 ng / ml to 1 pg / ml (microgram / milliliter).

[0049] Additionally, active agent-containing compositions may be in a variety of forms. The preferred form depends on the intended mode of administration and therapeutic application, which will in turn dictate the types of carriers / excipients. Suitable forms include, but are not limited to, liquid, semi-solid and solid dosage forms.

[0050] Pharmaceutical formulations adapted for oral administration may be presented, for example and without limitation, in capsules, tablets, oral solutions, or the like, and include suitable carriers and coatings as are broadly-known in the pharmaceutical arts.

[0051] Pharmaceutical formulations adapted for parenteral administration may be presented, for example and without limitation, in syringes, vials, bottles, IV / infusion bags, or the like, as are broadly-known to those of ordinary skill. Excipients include, for example and without limitation, water, saline, PBS, Lactated Ringers, or any other injectable carriers. Suitable emulsifiers, lipids, surfactants, or the like may be utilized to maintain an active agent in solution.

[0052] Pharmaceutical formulations adapted for transdermal administration may be presented, for example and without limitation, as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time or electrodes for iontophoretic delivery.

[0053] Pharmaceutical formulations adapted for topical administration may be formulated, for example and without limitation, as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.

[0054] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. For example, sterile injectable solutions can be prepared by incorporating the active agent in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, typical methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

[0055] The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of beingcompatible with the other ingredients of the formulation and not injurious to the subject being treated. Some examples of materials which can serve as pharmaceutically- acceptable carriers include: (1 ) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium state, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (1 1 ) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21 ) polyesters, polycarbonates, and / or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; and (22) other non-toxic compatible substances employed in pharmaceutical formulations. Such excipients or carriers, include vehicles for delivering RNA as described herein, such as, for example and without limitation, LNPs, liposomes, or other nanoparticle.

[0056] Pharmaceutically acceptable salts of any of the therapeutic agents described herein also may be used in the methods described herein. Pharmaceutically acceptable salt forms of the therapeutic agents described herein may be prepared by conventional methods known in the pharmaceutical arts, and include as a class veterinarily acceptable salts. For example and without limitation, where a therapeutic agent comprises a carboxylic acid group, a suitable salt thereof may be formed by reacting the compound with an appropriate base to provide the corresponding base addition salt. Non-limiting examples include: alkali metal hydroxides, such as potassium hydroxide, sodium hydroxide, and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, such as potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine, and N-methylglutamine.

[0057] Non-limiting examples of pharmaceutically-acceptable base salts include: aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts. Salts derived frompharmaceutically acceptable organic non-toxic bases include, without limitation: salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine, and tris-(hydroxymethyl)-methylamine (tromethamine).

[0058] Non-limiting examples of pharmaceutically-acceptable acid salts include: acetate, adipate, alginate, arginate, aspartate, benzoate, besylate (benzenesulfonate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate, galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate,2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, and phthalate.

[0059] Multiple salts forms are also considered to be pharmaceutically-acceptable salts. Common, non-limiting examples of multiple salt forms include: bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium, and trihydrochloride.

[0060] As such, “pharmaceutically acceptable salt” as used herein is intended to mean an active ingredient (therapeutic agent) comprising a salt form of any compound as described herein. The salt form preferably confers to the improved and / or desirable pharmacokinetic / pharmodynamic properties of the compounds described herein.

[0061] Drug products, or pharmaceutical compositions comprising an active agent (e.g., drug), may be prepared by any method known in the pharmaceutical arts, forexample, by bringing into association the active ingredient with the carrier(s) or excipient(s). As used herein, a “pharmaceutically acceptable excipient”, “carrier”, or “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable excipients include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the active agent. In certain aspects, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used in delivery systems, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are broadly-known to those skilled in the art.

[0062] The therapeutic agents described herein can be administered by any effective route. Examples of delivery routes include, without limitation: topical, for example, epicutaneous, inhalational, enema, ocular, otic, and intranasal delivery; enteral, for example, orally, by gastric feeding tube, and rectally; and parenteral, such as, intravenous, intraarterial, intrathecally, intramuscular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal, transdermal, iontophoretic, transmucosal, epidural, and intravitreal, with intrathecal and oral approaches being preferred in many instances. Suitable dosage forms may include single-dose, or multiple-dose vials or other containers, such as medical syringes, containing a composition comprising the therapeutic agent useful for treatment of graft rejection as described herein.

[0063] Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the therapeutic agent may be administered continuously or in a pulsed fashion with doses or partialdoses being administered at regular intervals, for example, every 10, 15, 20, 30, 45, 60, 90, or 120 minutes, every 2 through 12 hours daily, or every other day, etc., be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. In some instances, it may be especially advantageous to formulate therapeutic agents in dosage unit form for ease of administration and uniformity of dosage. The specification for the dosage unit forms may be dictated by and directly dependent on (a) the unique characteristics of the therapeutic agent and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic agent for the treatment of sensitivity in individuals.

[0064] Useful dosage forms include: intravenous, intramuscular, intrathecal, or intraperitoneal solutions, oral tablets, capsules, or liquids, topical ointments or creams, and transdermal devices (e.g., patches). The therapeutic agent may be provided in a sterile solution comprising the therapeutic agent and a solvent, such as water, saline, lactated Ringer’s solution, or phosphate-buffered saline (PBS), e.g., as a parenteral dosage form, such as an intrathecal infusion or injection. Additional excipients, such as polyethylene glycol, emulsifiers, salts, and buffers may be included in the solution.

[0065] Active agent-containing compositions may be in a variety of forms. The preferred form depends on the intended mode of administration and therapeutic application, which will in turn dictate the types of carriers / excipients. Suitable forms include, but are not limited to, liquid, semi-solid and solid dosage forms.

[0066] Pharmaceutical formulations adapted for transdermal administration may be presented, for example and without limitation, as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time or electrodes for iontophoretic delivery.

[0067] Pharmaceutical formulations adapted for topical administration may be formulated, for example and without limitation, as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.

[0068] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. For example, sterile injectable solutions can be prepared by incorporating the active agent in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion mediumand the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, typical methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

[0069] By “target-specific” or reference to the ability of one compound to bind another target compound specifically, it is meant that the compound binds to the target compound to the exclusion of others in a given reaction system, e.g., in vitro, or in vivo, to acceptable tolerances, permitting a sufficiently specific diagnostic or therapeutic effect according to the standards of a person of skill in the art, a medical community, and / or a regulatory authority, such as the U.S. Food and Drug Agency (FDA), in aspects, in the context of administering a reagent as described herein to LF tissue in a patient.

[0070] Compounds targeting the products of the genes described herein, such as VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1, may be developed or repurposed. Antisense and RNA interference reagents targeting the described genes are either commercially available or are readily developed, e.g., as described below. One aspect of the technology described herein is that drugs for targeting identified genes may have been developed for other purposes, such as treatment of cancer, and may be repurposed for treatment of graft rejection as described herein. These compounds include antibody reagents (including, for example and without limitation: antibodies, antibody fragments, nanobodies, scFv fragments, and the like, which are typically humanized as is broadly recognized), peptide reagents, and chemical compounds (e.g., “small molecules”).

[0071] Compounds targeting VEGFA include, without limitation: Avastin (bevacizumab, humanized mAb, Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun;86:102017 and de Aguiar RB, de Moraes JZ. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity inTumors. Front Immunol. 2019 May 9;10:1023), aflibercept, brolucizumab, ranibizumab, docetaxel, bevacizumab, oxaliplatin, pegaptanib, sorafenib, irinotecan, capecitabine, lenalidomide, OSI-632, bevasiranib, sunitinib, cisplatin, cilostazol, domatinostat, CDC-801 , squalamine, risuteganib, fluorouracil, muparfostat, phenytoin, gentamicin, fenofibrate, conbercept, milatuzumab, MP-0250, regorafenib, sildenafil, carboplatin, zaltrap, navicixizumab, elmiron, abicipar, celecoxib, leucovorin, enalapril, temozolomide, zoledronic, pemetrexed, cetuximab, fulvestrant, panitumumab, prednisone, IFNa2a, 5-fluorouracil, dalteparin, paclitaxel, gemcitabine, bevacizumab- irdye, etoposide, lomustine, 800cw, topotecan, olaparib, gefitinib, carmustine, erlotinib, thalidomide, atezolizumab, acid, vanucizumab, chelerythrine, faricimab, and entrectinib. These compounds are expected to be useful in treatment of graft rejection, e.g., T cell-mediated ACR.

[0072] Compounds targeting CXCL10 (IP-10, interferon-inducible ligand 10), include, for example and without limitation: anti-chemokine (C-X-C motif) ligand 10 antibody e.g., US 8,945,546 B2; Bonvin P, Gueneau F, Buatois V, Charreton-Galby M, Lasch S, Messmer M, Christen U, Luster AD, Johnson Z, Ferlin W, Kosco-Vilbois M, Proudfoot A, Fischer N. Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES. J Biol Chem. 2017 Mar 10;292(10):4185-4197. doi: 10.1074 / jbc.M1 16.745877), Eldelumab, also known as BMS-936557 (BMS=Bristol- Myers Squibb; see, e.g., Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50), NI-0801 (see, e.g., US 8,1 10,661 B2, Novimmune, humanized monoclonal antibody, also described in de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P. NI-0801 , an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Commun. 2018 Mar 23;2(5):492-503), atorvastatin, atropine, methylprednisolone, NI-0801 , oxaliplatin, regramostim, ritonavir, stavudine, testosterone, zidovudine, and MDX- 1 100. These compounds are expected to be useful in treatment of graft rejection, e.g., T cell-mediated ACR.

[0073] Compounds targeting CXCL13, include, for example and without limitation: alemtuzumab, chlorambucil, cyclophosphamide, fludarabine, necuparanib, NOX-A12, prednisone, rituximab, and vincristine. These compounds are expected to be useful in treatment of graft rejection, e.g., T cell-mediated ACR.

[0074] Compounds targeting CD74, include, anti-CD74 antibody reagents, for example and without limitation: milatuzumab (see, e.g., US 7,312,318 B2, describing humanized anti-CD74 antibodies)

[0075] The proteasome is a complex protease responsible for degrading unwanted or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. The primary proteasome is the 26S proteasome, which is composed of a core particle (20S) and one or two 19S regulatory particles. The genes encoding proteasomal subunits (proteasomal component genes) are grouped into those encoding the 20S core and those encoding the 19S regulatory complex. Additionally, there are genes for alternative proteasome regulators.

[0076] 20S Core Particle (CP) Genes: The 20S core is a barrel-shaped complex composed of four stacked rings: two outer a-rings and two inner [3-rings. Each ring is composed of seven distinct subunits, alpha and beta. Alpha Subunits include: PSMA1 (Proteasome Subunit Alpha Type-1 ), PSMA2 (Proteasome Subunit Alpha Type-2), PSMA3 (Proteasome Subunit Alpha Type-3), PSMA4 (Proteasome Subunit Alpha Type-4), PSMA5 (Proteasome Subunit Alpha Type-5), PSMA6 (Proteasome Subunit Alpha Type-6), and PSMA7 (Proteasome Subunit Alpha Type-7). Beta subunits include: PSMB1 (Proteasome Subunit Beta Type-1 ), PSMB2 (Proteasome Subunit Beta Type-2), PSMB3 (Proteasome Subunit Beta Type-3), PSMB4 (Proteasome Subunit Beta Type-4), PSMB5 (Proteasome Subunit Beta Type-5), PSMB6 (Proteasome Subunit Beta Type-6), PSMB7 (Proteasome Subunit Beta Type-7), PSMB8 (Proteasome Subunit Beta Type-8, also known as LMP7, part of the immunoproteasome), PSMB9 (Proteasome Subunit Beta Type-9, also known as LMP2, part of the immunoproteasome), and PSMB10 (Proteasome Subunit Beta Type-10, also known as MECL-1 , part of the immunoproteasome).

[0077] 19S Regulatory Particle (RP) Genes: The 19S regulatory particle consists of a lid and a base, with each having distinct subunits. Base Subunits include: , PSMC1 (Proteasome 26S Subunit, ATPase 1 ), PSMC2 (Proteasome 26S Subunit, ATPase 2), PSMC3 (Proteasome 26S Subunit, ATPase 3), PSMC4 (Proteasome 26S Subunit, ATPase 4), PSMC5 (Proteasome 26S Subunit, ATPase 5), PSMC6 (Proteasome 26SSubunit, ATPase 6), PSMD1 (Proteasome 26S Subunit, Non-ATPase 1 ), PSMD2 (Proteasome 26S Subunit, Non-ATPase 2), or PSMD3 (Proteasome 26S Subunit, Non-ATPase 3). Lid Subunits include, PSMD4 (Proteasome 26S Subunit, Non- ATPase 4), PSMD5 (Proteasome 26S Subunit, Non-ATPase 5), PSMD6 (Proteasome 26S Subunit, Non-ATPase 6), PSMD7 (Proteasome 26S Subunit, Non-ATPase 7), PSMD8 (Proteasome 26S Subunit, Non-ATPase 8), PSMD9 (Proteasome 26S Subunit, Non-ATPase 9), PSMD10 (Proteasome 26S Subunit, Non-ATPase 10), PSMD1 1 (Proteasome 26S Subunit, Non-ATPase 1 1 ), PSMD12 (Proteasome 26S Subunit, Non-ATPase 12), PSMD13 (Proteasome 26S Subunit, Non-ATPase 13), and PSMD14 (Proteasome 26S Subunit, Non-ATPase 14). Alternative Proteasome Regulators include: PA28a (PSME1 ), PA28[3 (PSME2), PA28y (PSME3), PA200 (PSME4), PA28s (PSME5).

[0078] These listed proteasomal genes encode the various subunits that come together to form the functional proteasome complex responsible for regulated protein degradation in eukaryotic cells.

[0079] Chemokine genes and their receptors include: 17 CXC chemokines, 28 CC chemokines, one CX3C chemokine (fractalkine), two XC chemokines, and approximately 23 known chemokine receptors. Chemokines include: CXCL1 through CXCL17, CCL1 through CCL28, CX3CL1 , XCL1 , XCL2, and IL-8. Chemokine receptors are a class of G protein-coupled receptors that bind chemokines and mediate their effects on target cells, and include: , CXCR1 (IL-8RA), CXCR2 (IL-8RB), CXCR3, CXCR4, CXCR5, CXCR6, CXCR7 (ACKR3, atypical chemokine receptor), CCR1 , CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CX3CR1 , XCR1 , ACKR1 (formerly DARC, Duffy antigen receptor for chemokines), ACKR2 (formerly D6), ACKR3 (formerly CXCR7, also classified under CXCRs), ACKR4 (formerly CCRL1 ).

[0080] Growth factors are a group of signaling proteins that play critical roles in the regulation of blood vessel formation (angiogenesis) and maintenance. Vascular growth factors include: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PIGF (Placental Growth Factor), FGF-1 , FGF-2, FGF-4, FGF-5, and other FGFs, PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, PDGF-AB, TGF-[31 , TGF-[32, and TGF-[33.

[0081] Immune synapse genes include: IL2RG, LCP1 , CD74, CD5, LTB, MICB, CD53, IDO1 , GZMA, CD97, HLA-DMB, CCL19, LCK, HLA-DRA, TIGIT, PTPRC, CD48, CCR2, CCL21 , and ENTPD1 .

[0082] It is noted that RNA interference reagents and antisense reagents have been, or readily can be developed for these proteasomal, chemokine, chemokine receptor, and growth factor gene targets using their mRNA / cDNA sequences as are broadly available (human and otherwise), for example in public databases such as GenBank, and can be readily accessed via those databases and via NCBI’s Gene database and the Online Mendelian Inheritance in Man (OMIM) database, or in the literature. Providing transcript sequences for every aforementioned gene product is therefore unnecessary, and unnecessarily burdensome, considering the state of the art, considering RNAi reagents are commercially available for many, if not most listed genes, e.g., from ThermoFisher Scientific, among others. See also, details below regarding design and synthesis of RNA interference and antisense oligonucleotides. Antibodies are commercially-available for most, if not all the products of the aforementioned genes, and can be prepared in humanized form by persons of ordinary skill.

[0083] Compounds targeting proteasomal components, e.g. PSMB9 and PSME1, include: Bortezomib (US 5,780,454 A, VELCADE, PS-341 (originally MG-341 , [(1 R)- 3-methyl-1 -[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino] butyl]boronic acid, Alwahsh M, Farhat J, Talhouni S, Hamadneh L, Hergenroder R. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J. 2023 Jan 16;22:146- 168), carfilzomib (Kyprolis), ixazomib (Ninlaro), and lenalidomide. These compounds are expected to be useful in treatment of graft rejection, e.g., T cell-mediated ACR.

[0084] In addition to the above, nucleic acid-based reagents, such as RNA interference and antisense reagents are expected to be useful in knocking down expression of genes that overexpress in allograft rejection patients, e.g., a patient suffering from ACR that us T cell-mediated. Unless stated otherwise, nucleotide sequences are recited herein in a 5' to 3' direction, and amino acid sequences are recited herein in an N-terminal to C-terminal direction according to convention.

[0085] The terms “transfect”, “transfection”, “transfected”, and like terms refer to the introduction of a gene into a eukaryotic cell, such as a cell of graft tissue or a PBMC or a subpopulation thereof, such as CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cell populations, and includes “transduction,” which is viral-mediated gene transfer, for example, by use of recombinant retrovirus(e.g., lentivirus), AAV, adenovirus (Ad), or any other applicable viral-mediated gene transfer platform.

[0086] Nucleic acids are biopolymers, or small biomolecules, essential to all known forms of life. They are composed of nucleotides, which are monomers made of three components: a 5-carbon sugar, a phosphate group and a nitrogenous base. If the sugar is a simple ribose, the polymer is RNA; if the sugar is derived from deoxyribose, the polymer is DNA. DNA typically uses the nitrogenous bases guanine, thymine, adenine, and cytosine. RNA typically uses the nitrogenous bases guanine, uracil, adenine, and cytosine.

[0087] By “expression” or “gene expression,” it is meant the overall flow of information from a gene. A “gene” is a sequence of DNA or RNA which codes for a molecule, such as a protein or a functional RNA, such as an ncRNA that has a function. A “gene” is a functional genetic unit for producing its gene product, such as RNA or a protein in a cell, or other expression system encoded on a nucleic acid and generally comprising: a transcriptional control sequence, such as a promoter and other c / s-acting elements, such as transcriptional response elements (TREs) and / or enhancers; an expressed sequence that typically encodes a protein (referred to as an open-reading frame or ORF) or functional / structural RNA; and a polyadenylation sequence). A gene produces a gene product (typically a protein, optionally post-translationally modified, or a functional / structural RNA) when transcribed. By “expression of genes under transcriptional control of,” or alternately “subject to control by” a designated sequence such as a promotor, it is meant gene expression from a gene containing the designated sequence operably linked (functionally attached, typically in cis) to the gene. A gene that is “under transcriptional control” of a promotor or transcription control element, is a gene that is transcribed at detectably different levels in the presence of a transcription factor, e.g., in specific cells, as further described below, and in the context of the present disclosure, produces a difference in transcription levels when expressed in a specific cell type. A “gene for expression of” a stated gene product is a gene capable of expressing that stated gene product when placed in a suitable environment, that is, for example, when transformed, transfected, transduced, etc. into a cell, and subjected to suitable conditions for expression. In the case of a constitutive promoter “suitable conditions” means that the gene typically need only be introduced into a host cell. In the case of an inducible promoter, “suitable conditions” means when factors that regulate transcription, such as DNA-binding proteins, are present or absent, forexample, an amount of the respective inducer is available to the expression system (e.g., cell), or factors causing suppression of a gene are unavailable or displaced - effective to cause expression of the gene.

[0088] In further detail, transcription is the process by which the DNA gene sequence is transcribed into RNA. The steps include transcript initiation, transcript elongation, and transcript termination. The molecular machinery of transcription includes but is not limited to: RNA polymerase, general transcription factors, enhancers, and promoter DNA, and RNA transcript. Transcription factors (TFs) are proteins that control the rate of transcription of genetic information from DNA to RNA, by binding to a specific DNA sequence (i.e., the promoter region). The function of TFs is to regulate genes in order to make sure that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism. The promoter region of a gene is a region of DNA that initiates transcription of that particular gene. Promoters are located near the transcription start sites of genes, on the same strand, and often, but not exclusively, are upstream (towards the 5' region of the sense strand) on the DNA. Promoters can be about 100-1000 base pairs long. Additional sequences and noncoding elements can affect transcription rates. If the cell has a nucleus (eukaryotes), the RNA is further processed. This includes polyadenylation, capping, and splicing. Polyadenylation is the addition of a poly(A) tail to a messenger RNA. The poly(A) tail consists of multiple adenosine monophosphates; in other words, it is a stretch of RNA that has only adenine bases. In eukaryotes, polyadenylation is part of the process that produces mature messenger RNA (mRNA) for translation. Capping refers to the process wherein the 5’ end of the pre-mRNA has a specially altered nucleotide. In eukaryotes, the 5’ cap (cap-0), found on the 5’ end of an mRNA molecule, consists of a guanine nucleotide connected to mRNA via an unusual 5’ to 5’ triphosphate linkage. During RNA splicing, pre-mRNA is edited. Specifically, during this process introns are removed, and exons are joined together. The resultant product is known as mature mRNA. The RNA may remain in the nucleus or exit to the cytoplasm through the nuclear pore complex.

[0089] Gene expression involves various steps, including transcription, post- transcriptional RNA modification, translation, and post-translational modification of a protein. Expression of a gene may also include reduction of the total amount of the protein product, such as by cleavage, sequestration, binding, or other means of decreasing the function or amount of a protein product.

[0090] Complementary refers to the ability of polynucleotides (nucleic acids) to hybridize to one another, forming inter-strand base pairs. Base pairs are formed by hydrogen bonding between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair (hybridize) in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. When using RNA as opposed to DNA, uracil rather than thymine is the base that is complementary to adenosine. Two sequences comprising complementary sequences can hybridize if they form duplexes under specified conditions, such as in water, saline (e.g., normal saline, or 0.9% w / v saline) or phosphate-buffered saline), or under other stringency conditions, such as, for example and without limitation, 0.1 X SSC (saline sodium citrate) to 10X SSC, where 1 X SSC is 0.15M NaCI and 0.015M sodium citrate in water. Hybridization of complementary sequences is dictated, e.g., by salt concentration and temperature), with the melting temperature (Tm) lowering with increased mismatches and increased stringency. Perfectly matched sequences are said to be fully complementary, or have 100% sequence identity (gaps are not counted, and the measurement is in relation to the shorter of the two sequences). In one aspect, a sequence that “specifically hybridizes” to another sequence, does so in a hybridization solution containing 0.5M sodium phosphate buffer, pH 7.2, containing 7% SDS, 1 mM EDTA, and 100 mg / ml of salmon sperm DNA at 65 ° C for 16 hours and washing twice at 65 °C for twenty minutes in a washing solution containing 0.5xSSC and 0.1 % SDS, or does so under conditions more stringent than 2X SSC at 65QC, for example, in 0.2X SSC at 55QC. A sequence that specifically hybridizes to another typically has at least 80%, 85%, 90%, 95%, or 99% sequence identity with the other sequence. For purposes of comparing sequence identity of an RNA sequence to that cDNA sequence, Ts and Us are interchangeable.

[0091] The term “homology” can refer to a percent (%) identity of an RNA to a reference RNA. As a practical matter, whether any particular RNA can be at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any reference RNA sequence of any RNA described herein (which may correspond with a particular nucleic acid sequence described herein), such particular RNA sequence can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention,the parameters can be set such that the percentage of identity is calculated over the full length of the reference RNA sequence and that gaps in homology of up to 5% of the total number of RNA bases in the reference sequence are allowed.

[0092] Production of useful nucleic acid constructs, such as recombinant viral vectors for production of nucleic acids, such as the genetic constructs and recombinant viral genomes described herein, is routine, in that molecular cloning and gene assembly methods are routine. Further, a number of companies can custom-synthesize and verify multi-kilobase genes, making the production of genes or genomes as described herein, such as recombinant viral genomes, routine (See, e.g., Gene Synthesis Handbook, 2d Edition, 2014, GenScript USA, Inc.).

[0093] The active agent for treatment of graft rejection, e.g. , T cell-mediated ACR, may be an RNA or RNA analog, such as an RNAi reagent as described below. Nanocarriers may be used to deliver nucleic acid reagents to graft or PBMC cells. Examples of microcarrier delivery include, without limitation: lipid nanoparticles (see, e.g. Hou, X., et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6, 1078-1094 (2021 )), exosomes (see, e.g., Amiri, A., et al. Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications. J Transl Med 20, 125 (2022)), liposomes (see, e.g., Xue HY, et al. Lipid-Based Nanocarriers for RNA Delivery. Curr Pharm Des. 2015;21 (22):3140-7), polymer nanoparticles, dendrimers, or any other useful delivery vehicle, including targeted methods using antibodies or other target-specific binding reagent (s ee, generally, for example, Paunovska, K., Loughrey, D. & Dahlman, J.E. Drug delivery systems for RNA therapeutics. Nat Rev Genet 23, 265-280 (2022)).

[0094] Lipid nanoparticles are small particles that are endocytosed by cells with their cargo, such as an RNA, which is released in the cell’s lysosomes. Examples of lipid nanoparticles include the formulations used for the BioNTech / Pfizer BNT162b2 and Moderna mRNA-1273 vaccines for delivery of mRNAs and patisiran for delivery of siRNA. Compositions of lipid nanoparticles are broadly-described, and typically include: an ionizable lipid, a helper lipoid, a cholesterol, a PEGylated (polyethylene glycol-functionalized) lipid, and RNA in specific ratios. The choice of constituents for the LNPs may determine delivery location, and the agent may be delivered systemically, locally, or to cells ex vivo for later delivery to the patient.

[0095] Other transfection methods may be used to deliver a nucleic acid reagent to cells. One alternative transfection method is by electroporation, by administering the agent, in any useful carrier or excipient, and, by using electrodes, e.g., a current isapplied that increases cellular permeability to facilitate passage of a nucleic acid into cells. Systems are commercially available that can be used for in vivo electroporation, such as the NEPA21 Super Electroporator equipped with in vivo, e.g., needle, electrodes (Nepa Gene Company, Ltd. Japan). Ultrasound (sonoporation) also may be used to deliver nucleic acids in vivo.

[0096] A nucleic acid reagent may be delivered by a transfected or transduced gene, for example by viral-based, or plasmid-based delivery. A miRNA or shRNA RNAi reagent can be produced from a gene for expressing the miRNA or shRNA, transferred by any suitable means, such as by recombinant vector such as a recombinant Adeno- associated virus (AAV), Adenovirus (Ad), or retrovirus (e.g., lentiviral) vector, or by gene editing, such as by CRISPR-Cas or TALENS methods, as are broadly-known. See, e.g., Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019 Mar 12;23:8 and Sharma D, et al., A review of the tortuous path of nonviral gene delivery and recent progress. Int J Biol Macromol. 2021 Jul 31 ;183:2055-2073, providing examples of viral and non-viral gene delivery methods.

[0097] RNA levels in a cell, e.g., mRNA levels, can be controlled post- transcriptionally. Native mechanisms, including: endogenous gene silencing mechanisms, interference with translational mechanisms, interference with RNA splicing mechanisms, and destruction of duplexed RNA by RNAse H, or RNAse H-like activity. As is broadly-recognized by those of ordinary skill in the art, these endogenous mechanisms can be exploited to decrease or silence mRNA activity in a cell or organism in a sequence-specific, targeted manner. Antisense technology typically involves administration of a single-stranded antisense oligonucleotide (ASO) that is chemically-modified, e.g., as described herein, for bio-stability, and is administered in sufficient amounts to effectively penetrate the cell and bind in sufficient quantities to target mRNAs in cells. RNA interference (RNAi) harnesses an endogenous and catalytic gene silencing mechanism, which means that once, e.g., a microRNA, or double-stranded siRNA has been delivered into the cytosol, they are efficiently recognized and stably incorporated into the RNA-induced silencing complex (RiSC) to achieve prolonged gene silencing. Either antisense technology or RNAi may be used effectively to knock-down or silence expression of a gene or gene product, such as VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1, or other genes described herein (see, e.g., Watts, J.K., et al. Gene silencing by siRNAs and antisenseoligonucleotides in the laboratory and the clinic (2012) 226(2):365-379). It should be noted that siRNAs and / or ASOs targeting VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1, or other genes described herein, are commercially available from sources such as GeneTools, Dharmacon, or Thermo Fisher Scientific, among many other sources, or are readily determined and synthesized based on broadly-known algorithms and calculators using an appropriate mRNA / cDNA sequence as input, such as, without limitation, SEQ ID NOS: 1 -6, or other versions or isoforms thereof, which may be identified, for example and without limitation, in NCBI’s Gene database (www.ncbi.nlm.nih.gov / gene). Based on the present disclosure, one of ordinary skill can design, and / or produce an active agent capable of knocking down VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 expression, or expression of other genes described herein. Of note, a number of publications describe algorithms for generating candidate iRNA sequences, and publicly-available software can be used to implement those algorithms. As such, typically, one only needs to enter an mRNA sequence into a calculator to produce candidate iRNAs. One siRNA, or multiple siRNAs targeting different portions of a target mRNA may be used.

[0098] The terms "iRNA," "RNAi agent," "RNAi agent," and "RNA interference agent" as used interchangeably herein, refer to an agent that contains RNA nucleotides, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, e.g., knocks down or silences, the expression of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA in a cell, e.g., a cell within a subject, such as a mammalian subject.

[0099] In one aspect, an RNAi agent includes a single stranded RNAi that interacts with a target RNA sequence, e.g., an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into double stranded short interfering RNAs (siRNAs) comprising a sense strand and an antisense strand by a Type III endonuclease known as Dicer. Dicer, a ribonuclease-lll-like enzyme, processes these dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs. These siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand toguide target recognition. Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing. Thus, in one aspect an RNAi is a single stranded RNA (ssRNA) (the antisense strand of an siRNA duplex) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene. Accordingly, the term "siRNA" is also used herein to refer to an interfering RNA (iRNA or RNAi agent).

[0100] In another aspect, the RNAi agent may be a single-stranded RNA that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded RNAs are described in U.S. Patent No. 8,101 ,348 and in Lima et al. (Single-stranded siRNAs activate RNAi in animals. Cell. 2012 Aug 31 ;150(5):883-94).

[0101] In another aspect, an "iRNA" or RNAi agent” for use in the compositions and methods described herein is a double stranded RNA and can be referred to herein as a "double stranded RNAi agent," "double stranded RNA (dsRNA) molecule," "dsRNA agent," or "dsRNA". The term "dsRNA", refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having "sense" and "antisense" orientations with respect to a target RNA, e.g., an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA. A double stranded RNA (dsRNA) may trigger the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional genesilencing mechanism referred to herein as RNA interference or RNAi.

[0102] The majority of nucleotides of each strand of a dsRNA molecule may be ribonucleotides, but as described in detail herein, each or both strands can also include nucleotide analogs, where one or more non-ribonucleotides, e.g., a deoxyribonucleotide and / or a modified nucleotide. In addition, as used in this specification, an "RNAi agent" or “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides. As used herein, the term "modified nucleotide" refers to a nucleotide having, independently, a modified sugar moiety, a modified inter-nucleotide linkage, and / or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to inter-nucleoside linkages, sugar moieties, or nucleobases. The modificationssuitable for use in the agents described herein include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by "RNAi agent" or “RNAi reagent” for the purposes of this disclosure.

[0103] The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 15-30 base pairs in length, for example, about 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21 , 15-20, 15- 19, 15-18, 15- 17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21 , 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21 , 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21 , 21 -30, 21 -29, 21 -28, 21 -27, 21 -26, 21 -25, 21 -24, 21 -23, or 21 -22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated.

[0104] The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a "hairpin loop." A hairpin loop can comprise at least one unpaired nucleotide. In some aspects, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23, or more unpaired nucleotides. The hairpin loop can be 10 or fewer nucleotides. The hairpin loop can be 8 or fewer unpaired nucleotides. The hairpin loop can be 4-10 unpaired nucleotides. The hairpin loop can be 4-8 nucleotides.

[0105] Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a "linker." The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are presentin the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.

[0106] An RNAi agent may be a dsRNA, each strand of which comprises 19-23 nucleotides, that interacts with a target RNA sequence, e.g., a VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, without wishing to be bound by theory, long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer. Dicer, a ribonuclease-l I l-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs. The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition. Upon binding to the appropriate target RNA, one or more endonucleases within the RISC cleave the target to induce silencing. In one aspect, an RNAi agent is a dsRNA of 24-30 nucleotides that interacts with a target RNA sequence, e.g., an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA sequence, to direct the cleavage of the target RNA.

[0107] "Complementary" sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs and / or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogstein base pairing.

[0108] The terms "complementary," "fully complementary," and "substantially complementary" herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of an RNAi agent and a target sequence, as will be understood from the context of their use.

[0109] As used herein, a polynucleotide that is "substantially complementary to at least part of a messenger RNA (mRNA)” refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA).

[0110] Accordingly, the antisense strand polynucleotides disclosed herein may be fully complementary to the target, e.g., VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA sequence. The antisense strand polynucleotides disclosed herein may be substantially complementary to the target VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA sequence and comprise a contiguous nucleotide sequencewhich has at least about 80% sequence identity to the nucleotide sequence of any of SEQ ID NOS: 1 -6 (FIGS. 1-6), or a fragment thereof, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

[0111] As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the duplex structure of an iRNA, e.g., a dsRNA. For example, when a 3’-end of one strand of a dsRNA extends beyond the 5'-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively, the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide / nucleoside analog, including a deoxynucleotide / nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5’-end, 3’-end or both ends of either an antisense or sense strand of a dsRNA.

[0112] In one example of the dsRNA, at least one strand comprises a 3' overhang of at least 1 nucleotide. In another example, at least one strand comprises a 3' overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11 , 12, 13, 14, or 15 nucleotides. In other examples, at least one strand of the RNAi reagent comprises a 5' overhang of at least 1 nucleotide. In certain examples, at least one strand comprises a 5' overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 1 1 , 12, 13, 14, or 15 nucleotides. In still other examples, both the 3' and the 5' end of one strand of the RNAi reagent comprise an overhang of at least one nucleotide.

[0113] In one example, the antisense strand of a dsRNA has a 1 - 10 nucleotide, e.g., a 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, overhang at the 3'-end and / or the 5'-end. In one example, the sense strand of a dsRNA has a 1 -10 nucleotide, e.g., a 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, overhang at the 3'-end and / or the 5'-end. In certain examples, the overhang on the sense strand or the antisense strand, or both, can include extended lengths longer than 10 nucleotides, e.g., 1 -30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, or 10- 15 nucleotides in length. In certain examples, an extended overhang is on the sense strand of the duplex. In certain examples, an extended overhang is present on the 3' end of the sense strand of the duplex. In certain examples, an extended overhang is present on the 5' end of the sense strand of theduplex. In certain examples, an extended overhang is on the antisense strand of the duplex. In certain examples, an extended overhang is present on the 3' end of the antisense strand of the duplex. In certain examples, an extended overhang is present on the 5' end of the antisense strand of the duplex. In another aspect, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

[0114] The terms "blunt" or "blunt ended" as used herein in reference to a dsRNA mean that there are no unpaired nucleotides or nucleotide analogs at a given terminal end of a dsRNA, that is, no nucleotide overhang. One or both ends of a dsRNA can be blunt.

[0115] Where both ends of a dsRNA are blunt, the dsRNA is said to be blunt ended. To be clear, a "blunt ended" dsRNA is a dsRNA that is blunt at both ends, that is, no nucleotide overhang at either end of the molecule. Most often such a molecule will be double stranded over its entire length.

[0116] The term "antisense strand" or "guide strand" refers to the strand of an iRNA, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., a VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA. As used herein, the term "region of complementarity" refers to the region on the antisense strand that is substantially complementary to a sequence, for example, a target sequence, e.g., a VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA sequence, e.g., as described herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, 3, or 2 nucleotides of the 5'- and / or 3’-terminus of the iRNA.

[0117] The therapeutic agent may be an antisense oligonucleotide (ASO). As used herein, “antisense oligonucleotides (ASOs)” are single-stranded, chemically-modified chains of multiple nucleotides having a sequence that is complementary to the sequence of the target gene’s transcribed messenger RNA (mRNA) within a cell. ASOs may be designed and purchased from commercial sources based on known transcript sequences (e.g., GeneTools, providing morpholino ASO reagents for may targets, as well as custom synthesis). The ASO may target VEGF (Koizumi K, Shintani T, Hayashido Y, Hamada A, Higaki M, Yoshioka Y, Sakamoto A, Yanamoto S, Okamoto T. VEGF-A promotes the motility of human melanoma cells through the VEGFR1 -PI3K / Akt signaling pathway. In Vitro Cell Dev Biol Anim. 2022Sep;58(8):758-770, describing purchased morpholino antisense ASOs specific for VEGFR1 or VEGFR2 (GeneTools, Philomath, OR)), or other gene products, such as the products of CD74, CXCL10, CXCL13, PSMB9, or PSME1, or other genes described herein, whether or not druggable, in view of the broad availability of RNAi products, which can be readily verified, for example as in the Examples below.

[0118] The ASO may be from 12 to 20 nucleotides, e.g., 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides, in length. The nucleotides may be chemically modified to comprise a 2'-0-methoxyethyl (MOE) sugar moiety, a 2'-O-methyl (OMe) sugar moiety, or a morpholino sugar moiety. The nucleotides may be linked through a phosphorothioate linkage.

[0119] The ASO, the pharmaceutically-acceptable salt of the ASO, or the solvate of the ASO may be in the form of a parenterally-injectable solution. Injectable solutions may include an effective amount of ASO of at least about 0.5 milligrams per milliliter (mg / mL), at least 1 mg / mL, at least 2 mg / mL, at least 3 mg / mL, from at least 0.5 mg / mL to at least 3 mg / mL, from at least 1 mg / mL to at least 3 mg / mL, from at least 2 mg / mL to at least 3 mg / mL, such as 2.4 mg / mL.

[0120] The ASO, the pharmaceutically-acceptable salt of the ASO, or the solvate of the ASO may be delivered to the patient parenterally in a dosing regimen. For example, the ASO , the pharmaceutically-acceptable salt of the ASO, or the solvate of the ASO may be administered to the patient in four loading doses and then may be administered every four months thereafter. For example, in the first year, the ASO, the pharmaceutically-acceptable salt of the ASO, or the solvate of the ASO may be administered parenterally, followed by a second parenteral injection approximately 14 days later, followed by a third parenteral injection approximately 14 days after the second parenteral injection, and followed by a fourth parenteral injection approximately 30 days after the third parenteral injection. The patient may then be administered a fifth parenteral injection approximately 4 months after the fourth parenteral injection, a sixth parenteral injection approximately 4 months after the fifth parenteral injection, and a seventh parenteral injection approximately 4 months after the sixth parenteral injection. The patient may then be administered parenteral injections every approximately 4 months thereafter.

[0121] It is understood that the sequence of the VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA must be sufficiently complementary to the antisense strandof the RNAi agent for the agent to be used in the indicated patient, e.g., human, mammalian, or vertebrate species.

[0122] The term "inhibiting," as used herein, is used interchangeably with "reducing," "silencing," "downregulating," "suppressing," "knocking down," and other similar terms, and includes any level of inhibition.

[0123] The phrase "knocking down or silencing of a specified RNA”, such as VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, as used herein, includes inhibition of expression of any VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene (such as, e.g., a mouse VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene, a rat VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene, a monkey VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene, or a human VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene) as well as variants or mutants of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene, in its production of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, affecting the stability of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, such as by antisense or RNAi technologies. "Knocking down or silencing of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA" includes any level of inhibition of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, e.g., at least partial suppression of the expression of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, such as an inhibition by at least about 20%. In certain aspects, inhibition is by at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0124] The expression of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA may be assessed based on the level of any variable associated with VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA expression, e.g., VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA level. The expression of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA may also be assessed indirectly based on assay of physiological markers associated with decreased expression of the VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA in a patient, such as a marker of transplant rejection.

[0125] In one example, at least partial suppression of the expression of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA, is assessed by a reduction of the amount of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA that can be isolated from or detected in a cell or group of cells, e.g., in a PBMC or graft tissue cell. A reduction of the amount of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA in a cell or tissue in which an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 gene is transcribed and which has been treated such that the expression of an VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 RNA is inhibited, may be determined as compared to a second cell or tissue substantially identical to the first cell or tissue but which has not been so treated (control cells), e.g., obtained and cultured from a biopsy. The degree of inhibition may be expressed in terms of:

[0126] The phrase "contacting a cell with an RNAi agent," such as a dsRNA or ASO, as used herein, includes contacting a cell by any possible means. Contacting a cell with an RNAi agent includes contacting a cell in vitro with the iRNA or contacting a cell in vivo with the iRNA. The contacting may be done directly or indirectly. Thus, for example, the RNAi agent may be put into physical contact with the cell by the individual performing the method, or alternatively, the RNAi agent may be put into a situation that will permit or cause it to subsequently come into contact with the cell. Further, an shRNA RNAi agent can be produced from a gene for expressing an shRNA, transferred by any suitable means, such as by recombinant vector such as a recombinant Adeno-associated virus (AAV) or retrovirus vector, or by gene editing, such as by CRISPR-Cas or TALENS methods, as are broadly-known. These technologies are broadly-known by those of ordinary skill and resources, such as suitable vectors and production systems are broadly-available, including from commercial sources.

[0127] Contacting a cell in vitro (e.g., ex vivo) may be done, for example, by incubating a cell with the RNAi agent. Contacting a cell in vivo may be done, for example, by injecting the RNAi agent into or near the tissue where the cell is located, such as a tumor, or by injecting the RNAi agent into another area, e.g., the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the RNAi agent may contain and / or be coupled to a ligand, e.g., GalNAc3, which directs the RNAi agent toa site of interest, e.g., a liver allograft. Combinations of in vitro and in vivo methods of contacting are also possible. For example, a cell may also be contacted in vitro (ex vivo) with an RNAi agent and subsequently transplanted into a subject.

[0128] Contacting a cell with an iRNA may include "introducing" or "delivering the iRNA into the cell" by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided diffusive or active cellular processes, or by use of auxiliary agents or devices. Introducing an iRNA into a cell may be in vitro and / or in vivo. For example, for in vivo introduction, iRNA can be injected into a tissue site, e.g., a graft, or administered systemically. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are known in the art.

[0129] As used herein, and further to the discussion above regarding iRNA reagents, “agent” or “RNAi agent,” when used in the context of an antisense, RNAi, or other single-stranded or double-stranded RNA interfering nucleic acids, refers not only to RNA structures, but effective nucleic acid analog structures. In antisense and RNAi technologies, use of RNA poses significant delivery issues due to the lability of RNA molecules. As such, RNA is commonly chemically-modified to produce nucleic acid analogs, not only to enhance stability of the nucleic acid molecules, but often resulting in increased binding affinity, and with reduced toxicity. Such modifications are broadly- known to those of ordinary skill in the art, and are available commercially (see, e.g., Corey, D.R., Chemical modification: the key to clinical application of RNA interference? (2007) J Clin lnvest.1 17(12):3615-3622, also describing RNAi, and United States Patent Application Publication No. 2017 / 0081667, incorporated herein by reference for its technical disclosure). Non-limiting examples of modifications to the nucleic acid structure in nucleic acid analogs include: modifications to the phosphate linkage, such as phosphoramidates or phosphorothioates; sugar modification, such as 2'-O, 4'-C methylene bridged, locked nucleic acid (LNA), 2’-methoxy, 2'-O- methoxyethyl (MOE), 2’-fluoro, S-constrained-ethyl (cEt), and tricyclo-DNA (tc-DNA); and non-ribose structures, such as phosphorodiamidate morpholino (PMO) and peptide-nucleic acids (PNA).

[0130] As above, RNAi reagents, such as an siRNA, may have 100% sequence identity with a portion or fragment of any one or more of SEQ ID NOS: 1 -6, or a sequence complementary thereto, or may include one or more additional nucleobases at their 3’ or 5’ end, or may include one or more substitutions that do not substantiallyinterfere with the activity of the RNAi agent in knocking down or silencing VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 expression. Also, SEQ ID NOS: 1 -6 are exemplary mRNAs of isoforms of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME 1. Alleles, mutations, or other variants or polymorphisms (e.g., single-nucleotide polymorphisms, SNPs) of VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1 sequences are possible, and as such effective agents, such as RNAi and antisense agents may be substituted to accommodate those variants. Further, some sequence mismatches in RNAi agents are not only tolerated, but may be beneficial (see, e.g., Wu, H., et al. “Improved siRNA / shRNA Functionality by Mismatched Duplex” PLoS One. 2011 ; 6(12): e28580). As such, sequences having up to 90% or 95% (two or one mismatches, respectively) sequence identity with SEQ ID NOS: 1 -6 are expected, in many circumstances, to be effective RNAi agents.

[0131] In aspects, a useful antisense oligonucleotide, e.g., a nucleic acid or nucleic acid analog, comprises a sequence having at least 90% sequence identity, at least 95% sequence identity, or 100% sequence identity with one of SEQ ID NOs: 1 -6. In aspects, the antisense oligonucleotide is an LNA.

[0132] Using the processes described herein, druggable targets for treatment of ACR, and in general, transplant rejection were discovered. Drugs targeting the identified targets are known and have been used for other indications, such as for treatment or cancer, and can be repurposed for use in preventing long-term transplant rejection. Further, the methods allow a practitioner: to predict transplant rejection with a peripheral blood (non-invasive) single-cell gene expression signature which classifies transplant rejection by druggable mechanisms; to diagnose transplant rejection with a peripheral blood (non-invasive) single-cell gene expression signature which classifies transplant rejection by druggable mechanisms; to predict transplant rejection with a tissue-based (non-invasive) proteogenomic signature which classifies transplant rejection by druggable mechanisms; to diagnose transplant rejection with a tissuebased (non-invasive) proteogenomic signature which classifies transplant rejection by druggable mechanisms; and to use a combined blood based and tissue-based signature to predict and diagnose transplant rejection and predict optimal drug(s) therapy based on these signatures

[0133] The methods maximize predictive and diagnostic accuracy through use of: peripheral blood single-cell transcriptional gene signatures measured with NGS (next generation sequencing), FISH (fluorescence in situ hybridization), or other sequencingand / or hybridization technologies in blood cell subsets defined by cell-specific genes and proteins and combinations thereof; transcriptional signatures defined with spatial analysis of regions and single cells within tissues which have been measured with NGS or FISH or similarly-functional technologies, and which use cell-specific genes and proteins and combinations thereof; and algorithmic combinations of those methods. The predictive signatures are embodied in algorithmic combinations of genes differentially expressed in two or more cells in peripheral blood and / or in tissue, or combinations of both, and the diagnostic signatures are embodied in algorithmic combinations of the signatures with covarying and / or co-expressed genes for cell- or antibody-mediated damage in blood or tissue or combinations of blood and tissue.

[0134] The gene sets include: i) common genes that are differentially expressed in 2 or more peripheral blood cell subsets by single cell RNA sequencing; ii) common genes that are differentially expressed in two or more subunits of tissue architecture, or two or more cells that make up a unit of tissue architecture or combinations thereof; and iii) differentially expressed genes for cell- or antibody-mediated damage in blood or tissue or combinations of blood and tissue, that covary or are co-expressed with genes in i) or II) or combinations of i) and II).

[0135] Identified through use of the methods described above, and exemplified in the examples below, are druggable targets and related drugs. Druggable targets include gene expression products of a proteasomal component gene, a CD74 gene, a chemokine gene, and / or a VEGF gene. Those genes include: VEGFA, CD74, CXCL10, CXCL13, PSMB9, or PSME1.

[0136] Further to the details regarding RNAi and ASO reagents referenced above, genes described herein, including classes thereof, are well-characterized, to the point that their sequences are publicly-available in or through various databases, such as NCBI GenBank. The sequences (typically cDNA sequences) of transcripts of any given gene described herein are known, and are useful for production of RNA interference reagents, or antisense reagents for knocking down expression of a given gene. RNA therapy methods are broadly-described, including methods of identification of useful sequences, and useful delivery methods are described in the literature (see, e.g., Friedrich M, Aigner A. Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs. 2022 Sep;36(5):549-571 ; Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Then 2020 Jun 19;5(1 ):101 ; Zhang X, Hai L, Gao Y, Yu G, Sun Y. Lipidnanomaterials-based RNA therapy and cancer treatment. Acta Pharm Sin B. 2023 Mar;13(3):903-915). With the cDNA sequence in hand, siRNA or shRNA oligonucleotides may be identified using various tools, available broadly (see, e.g., Ui- Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004 Feb 9;32(3):936-48). Sequences of exemplary transcripts are provided in FIGS. A-F. Further, with the name of the gene, RNAi reagents may be identified in a public database (see, e.g., Dar SA, Gupta AK, Thakur A, Kumar M. SMEpred workbench: A web server for predicting efficacy of chemically-modified siRNAs. RNA Biol. 2016 Nov;13(1 1 ):1144-1 151 and Chalk AM, Warfinge RE, Georgii-Hemming P, Sonnhammer EL. siRNAdb: a database of siRNA sequences. Nucleic Acids Res. 2005 Jan 1 ;33(Database issue):D131 -4, among others), or purchased from any commercial source, such as ThermoFisher SILENCER® or AMBION® products, Dharmacon ON-TARGETplus™ or Accell™ products, or OriGene, among others.

[0137] Viral delivery of miRNA and shRNA (iRNA) may be accomplished using any of a number of commercially-available and well-characterized cloning vector systems for producing recombinant viral transducing particles with shRNA expression, such as are available commercially from Charles River, OriGene, and Addgene, among many others. Non-limiting examples of suitable viral vectors include lentiviral or retroviral, adenoviral, adeno-associated virus, or herpesvirus vector systems. The nucleic acids are optionally, and preferably in many instances, recombinant, packaged viral genomes (nucleic acid that can be packaged into a viral particle), such that the nucleic acid is part of a transduction particle by which a cell can be transfected, as is broadly- known.

[0138] The cDNA sequences shown in FIGS. A-F are exemplary sequences of isoforms of VEGFA, CD74, CXCL10, CXCL13, PSMB9, and PSME1. Useful ASO or RNAi reagents may be designed based on these sequences or variants and isoforms thereof that are broadly-available publicly. Sequences of additional genes identified as being overexpressed in rejector PBMCs or grafts may likewise be used to produce RNAi or ASO reagents without undue experimentation.

[0139] Druggable proteasomal genes that are differentially overexpressed in PBMCs or graft tissue of transplant-rejection patients, include, for example and without limitation, PSMB9 and PSME1. Exemplary sequences for PSMB9 and PSME1 areprovided in FIGS. A and B. An exemplary sequence for druggable CD74 gene is provided in FIG. C. Druggable chemokine genes that are differentially overexpressed in PBMCs or graft tissue of transplant-rejection patients, include, for example and without limitation, CXCLW or CXCL13. Exemplary sequences for CXCLWor CXCL13 are provided in FIGS. 4 and 5. An exemplary sequence for a druggable VEGF gene (VEGFA) is provided in FIG. 6.Examples

[0140] Transplant Rejection has traditionally been classified as T-cell mediated and driven largely by cytokine signaling and cell-mediated damage by cytotoxic T-cells, or antibody-mediated, and mediated by antibodies produced by B-cells and plasma cells, which are in turn derived from B-cells which have recognized the foreign antigen, and have differentiated into antibody-secreting B-cells and plasma cells.

[0141] Traditional drug discovery / drug management of rejection: Traditional drugs were either derived from cancer drugs that inhibited cell proliferation (azathioprine), or suppressed cells non-specifically (steroids), or were just strong antiproliferative drugs (mycophenolate mofetil). These drugs targeted many cells that were capable of dividing rapidly. Calcineurin inhibitors like cyclosporine and tacrolimus inhibited cytokines, and thus saw their greatest effect in cells in which activation and immune response is largely dependent on cytokines (example T-cells NK cells). A more recent drug called rapamycin inhibited cell proliferation like the previously mentioned antiproliferative drugs, but acted by binding to a similar class of molecules as the calcineurin inhibitors. Drugs other than these small molecules included antibodies that blocked the IL2 receptor, or which depleted immune cells nonspecifically. A fusion protein belatacept inhibits costimulation, and was approved in 2011. Since then, no drugs have been approved to treat transplant rejection. The calcineurin inhibitors are used with steroids for lifelong immunosuppression. The antibodies are often used during periods or acute need such as acute rejection. The antiproliferative drugs are added to maintenance in those patients prone to severe, or recurrent rejection. These treatment approaches are often sequentially used, after trial and error.

[0142] If these drugs fail, we now use several new drugs which are approved for other indications Examples are the complement inhibitors, rituximab or bortezomib for antibody mediated rejection. No formal trials have been done for these drugs. Single center studies, or modest multi-center datasets that include anecdotal use has guided the adoption of these drugs. Because these drugs are used when others fail,cumulative toxicity due to previously used traditional drugs is often blamed on these newer and highly targeted agents. Upfront use of these targeted agents could improve efficacy, and limit toxicity if guided by mechanistic studies and documentation of appropriate targets.

[0143] The path forward: Our studies suggest that in addition to being cytokine- mediated, acute cellular rejection may be mediated predominantly by the upregulation of (druggable) proteasome-dependent processes, chemokine signaling, drivers of MHC-class II antigen presentation, and vascular / growth factor signaling. These terms could just as well be used to stratify rejection by druggable mechanisms.

[0144] These studies utilized a novel approach to define these drug targets and associated mechanisms, define novel drug targets for clinical treatment of rejection with novel drugs. To achieve this, blood and / or biopsy samples are obtained, and expression of genes and / or proteins are measured in blood (bulk or single cell) or biopsies regions typically affected in rejection of the different organs (such as portal or pericentral regions in liver, tubules or endothelial cells in the kidney, etc., single cells in biopsies, or in both blood and biopsies, if possible. Expression of chemokines, for example CXCL10 and CXCL13, or their receptors may be measured. Expression of proteasomal component genes may be measured, for example PSMB9, PSME1 or PSME2. Expression of vascular / other growth factor genes may be measured, such as VEGFA as an example. Expression of these genes in the clinical / test biopsy or blood sample is compared to that seen in reference datasets from tissue with no rejection to determine whether these genes are upregulated. Drugs are selected for use based on upregulated genes in the abovementioned classes. From a diagnostic and treatment standpoint, if genes are not upregulated, the biopsy is not consistent with rejection.Example 1

[0145] Here, scRNAseq of peripheral blood mononuclear cells (PBMC) was used to identify suggestive molecular mechanisms because of modest transcriptional differences between outcome groups. Mechanisms were corroborated with ST of LT biopsies in regions with histological changes of rejection. Performed for allograft dysfunction, these biopsies were obtained from children with or without ACR within 90 days after LT. Early time points were selected because early ACR occurs despite therapeutic immunosuppression and is less likely to have been precipitated byprotocolized minimization of immunosuppression conducted routinely after transplantation.Materials and MethodsHuman Subjects

[0146] Subjects included 11 males and 7 females, mean ± SEM age 10.97 ± 2.57 years, 9 each without (NR) and with (R) biopsy-proven acute cellular rejection (ACR). Rejection was graded as mild in 8 and moderate in one. Blood samples were collected 15.66±4.76 days (mean ± SEM) before the rejection event in rejectors. The indications for LT were biliary atresia-5, maple syrup urine disease-7, cystic fibrosis-1 , cirrhosis due to total parenteral nutrition-1 , propionic acidemia-1 , primary sclerosing cholangitis-1 , Alagille’s syndrome- 1 and autoimmune liver disease-1. In the 90-day period after LT, anti-HLA donor-specific antibody (DSA) were identified in five of 9 R and 1 of 9 NR (p=0.04, Fisher exact). The peak mean±SD fluorescence intensity of DSA measured with single antigen coated beads was higher among R, 5100±1591 and occurred earlier after LT, 34±4 days compared with MFI 3090, 75 days after LT in one NR. DSA resolved within 12 months after LT.

[0147] Sample collection: PBMC were obtained whole blood collected in sodium heparin tubes, before and within 90 days after LT from 18 children, of whom 9 experienced biopsy-proven early ACR based on Banff criteria (rejectors, R), and 9 who did not experience ACR (non-rejectors, NR). Spatial transcriptomics was performed in corresponding formalin-fixed paraffin-embedded (FFPE) biopsies from 5 of 9 R and 2 of 9 NR (Visium, 10XGenomics). All biopsies were performed for suspected rejection based on elevated liver function tests and absence of vascular occlusion or bile duct obstruction on imaging studies. DSA were characterized with single antigen coated beads (Luminex).Single Cell RNA sequencing (scRNA)

[0148] We performed single cell RNA sequencing (scRNAseq) of PBMC obtained before and within 90 days after LT from 18 children, of whom 9 experienced biopsy- proven early acute cellular rejection (R), and 9 did not (NR). The libraries generated for single cell RNA sequencing using Chromium 3’ v3 scRNAseq Library Kit (10X genomics, CA) according to the manufacturer instructions at the Single Cell Core lab at the University of Pittsburgh. The input of 4500-5000 PBMC cells used per sample. Data yield approximated 2000-2500 cells / sample. The libraries were sequenced in theUPMC genome Center using Novaseq 6000 instrument (Illumina, CA) to get up to 20,000 reads per cell.Spatial transcriptomics of formalin-fixed paraffin-embedded (FFPE) biopsies:

[0149] Sample preparation: The spatial transcriptomics of corresponding FFPE biopsies from 5 of 9 R and 2 of 9 NR was performed with the Visium Spatial for FFPE Gene Expression Starter Kit, Human Transcriptome (10x genomics, CA). Biopsies were only performed for elevated liver function tests after LT. All rejection events were biopsy-proven. Single antigen coated beads (Luminex) were used for DSA testing. The FFPE sectioned tissue is placed on a 6.5mm x 6.5mm capture area of the 10XGenomics Visium slide with 5,000 barcoded spots, each containing millions of oligos Oligos include a 16 nucleotide (nt) spatial barcode for location, a 30 nt poly(dT) sequence for mRNA capture, a 12 nt Unique Molecular Index (UMI) unique for each transcript bound by the probe, and an Illumina Read 1 sequence for use in library preparation and sequencing. Tissue is deparaffinized and stained with hematoxylin- eosin. Microscopic imaging is performed and subsequently used to overlay gene expression patterns. Stained tissue is decrosslinked to release RNA, specific probes covering the whole transcriptome are added to capture free mRNA targets, and probe pairs that have hybridized to RNA are ligated using a ligase. Tissue is treated with RNase and permeabilized to release ligation products which are then captured on the Visium slides. Captured ligation products are extended by a polymerase to incorporate a complement of the Spatial Barcode sequence and UMI. The spatially barcoded, ligated probe products are released from the slide and PCR-amplified using common sampleindexing primers. The final library is sequenced at a depth of 25k raw reads per capture spot covered by tissue in most FFPE samples in the UPMC genome Center using Novaseq 6000 instrument. Sequencing data is aligned with the image using barcode information for location and SpaceRanger, (10x Genomics, CA). Each barcoded spot is 55um in diameter with 100um center to center distance between spots. Thus, there is an average of 5-10 cells per spot depending on tissue cellular density. Images are visualized with Loupe Browser.

[0150] Statistical Analysis-scRNAseq: Cell Ranger (10x Genomics Cell Ranger 3.1.0) was used to demultiplex, align (hg38), and quantify reads. For each pool of 12 samples, 30,000 cells were expected to be recovered. Seurat was then used to QC, normalize, and identify anchor genes within each sample. Annotation of clusters was conducted with reference genes known to be uniquely expressed within each cell type.We identified cell populations in post-LT samples, identified genes discriminant between R and NR within each cell population, and repeated this exercise with pre- LT samples. Next, we identified those genes within each cell population that were uniquely present in post-LT samples and absent in pre-LT samples. Finally, we performed pathway analysis on these genes within each cell population. We searched for predicted upstream regulators of differential expression of genes (DEGs) in each cell cluster, used the Ingenuity Pathway Analysis “Upstream Analysis” tool (Kramer), and selected “Transcriptional Regulator” as a “Molecule Type” filter term to identify statistically significant upstream regulatory Transcription Factors (TF). Statistical significance was calculated using the right-tailed Fisher Exact Probability Tests; TF showing a p-value < 0.05 were considered statistically significant. The activity status of TF was determined by calculating the activity z-score, which is a statistical measure of how closely the expression pattern of TF-target genes present in the uploaded dataset compares to the expected pattern based on the literature findings. A positive score indicates an overall increase in activity, whereas a negative value indicates an overall decrease.

[0151] Statistical Analysis Spatial Transcriptomics: Data processing: BCL files from the sequencing results were converted into FASTQ files. The Space Ranger pipeline from 10X Genomics Space Ranger 1.3.1 was used to process the spatial transcriptomics (ST) data. Reads were mapped to the human GRCh38 genome assembly using the STAR v.2.6.1 63, and the gene count matrices from the Space Ranger pipeline were converted into a Seurat object and downstream analysis was performed using the R package, Seurat (v.3.2.2).64 Pre-processing of the ST datasets include removing of spots with more than 8% mitochondrial genes or fewer than 150 detected gene counts were discarded. The SCTransform normalization was used to normalize the gene-spot matrices followed by screening of the hypervariable genes. The objects from each of the biopsy sample were integrated using the Seurat anchorbased integration workflow followed by dimensionality reduction on the most significant components. The identified clusters were visualized in lowdimensional space using Uniform Manifold Approximation and Projection (UMAP), and the corresponding spot coordinates were visualized by superimposing on the images. Differential gene expression analysis between the rejectors and the non-rejectors was performed, and the representative markers for each cluster was selected at a threshold of (adjusted P-value < 0.05, |log2 FC| > 0.25) based on Benjamini-Hochbergcorrection. The functional enrichment analysis of the marker genes was estimated using different enrichment tools and algorithms, i.e., g:Profiler (a web server for functional enrichment analysis); and gene set enrichment analysis using clusterProfiler 4.0 66. Statistical analyses were performed using R version 4.2.1.

[0152] Cell-type deconvolution analysis Publicly available Human scRNA-seq liver cell atlas data from the Guilliams group at VIB-UGent (accessed 2022-04-01 ) was downloaded and analyzed to complement the spatial data in our studies. The scRNA- seq count data along with the metadata information indicating the cell types, and sample information for each cell was used as the reference. Thereafter, we implemented Conditional AutoRegressive Model-Based Deconvolution (CARD, using the R based package) for spatially informed cell type deconvolution based on cell type specific expression using the reference scRNA-seq data. Briefly, the CARD object was created using the sparse matrix of the raw scRNA-seq count data, a data frame containing the single cell metadata information, sparse matrix of the raw spatial resolved transcriptomics count data, and the spatial location with the x and y coordinates. The cell type proportion matrix was jointly visualized as the scatterpie plot. We then facilitated the construction of a refined spatial tissue map, and the cell type proportion of individual markers genes were visualized at an enhanced resolution.

[0153] Spatial weighted gene co-expression network analysis: An overview of the WGCNA methodology to process single cell data is as previously described (Langfelder P, and Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559). We investigated the spatialrelevant gene coexpression modules using the SCoexp module from CellTrek. For cells of interest, we first calculated a spatial-weighted gene cross-correlation matrix using the cell-gene expression matrix. Co-expression module detection was done using the consensus clustering approach with a default K through 2 to 8 and repetition of 20. For the identified coexpression modules, we calculated the cell-level module activity score, and then investigated the module scores at the spatial level.

[0154] Approach to analyzing regional transcriptomes: First, we localized potential regions of interest (ROIs) by: a) identifying distinct cell clusters and genes unique to each cluster, and evaluated each cluster for cholangiocyte-specific and pericentralregion-specific genes. The two ROIs where the lymphocyte-rich infiltrate of ACR is found include the cholangiocyte-rich portal region, and the pericentral region with high expression of the glutamate-ammonia ligase gene, GLUL; and b) identifying DEGsrelated to transplant-related T-cell and B-cell functions and antibody production in R versus NR comparisons in each cluster. We used gene ontology gene sets for T-cell receptor signaling, T-cell proliferation and T-cell-mediated cytotoxicity (GO 0050852, 0042098, and 0001913); B-cell receptor signaling (GO 0019882), antigen processing and presentation (GO 0050853), and Immunoglobulin production (GO 0002381 ); and c) localizing clusters to where they were most represented in corresponding biopsies after the pathologist (MRM) had independently identified the two ROIs in each biopsy. Second, we identified DEG associated with R (compared with NR) within cell clusters that colocalized with ROIs. For further analysis, we selected immune function DEGs that were also differentially expressed in R vs NR comparison in any PBMC subset. Third, we applied enrichment analysis using G-profiler 65 and IPA to search for common and different immune mechanisms of rejection between portal and pericentral ROIs, and potentially druggable novel targets. Finally, we deconvoluted these DEGs to estimate the proportional contribution of common types of immune cell to the transcriptome of the portal and pericentral regions.

[0155] Enrichment analysis: Pathway enrichment analysis was performed with G- profiler and further refined with protein-protein interactions in STRING 72. Top-ranked transcription factor (TF) motifs among DEGs were identified with Enrichr 38. ChlP-seq data from ENCODE 73 was evaluated to confirm TF binding motifs within 3KB of the transcription start site.

[0156] Immunostaining: To further identify molecular and cellular interactions, we identified genes coexpressed with cell-specific genes for dendritic cells, T-cells, macrophages, neutrophils and NK / NKT cells. We also performed immunofluorescence staining of CD74 and macrophage markers to confirm localization indicated by deconvolution of DEGs and co-expression analysis. Immunostaining for MAC387 identifies recently infiltrated macrophages whereas the CD68 labels multiple types of macrophages including circulating and tissue resident types. Finally, we identified regions most likely to contribute to circulating DSA, by comparing regional transcriptomes of biopsies with rejection, which was accompanied by circulating DSA in 2 recipients versus 3 recipients without DSA.RESULTS

[0157] LT affects PBMC subset distribution: We identified 1 1 PBMC clusters in 18 pretransplant samples, and 10 clusters in 18 post-transplant samples, each with unique anchor genes. Two clusters in pre-transplant and one in post-transplant samples, allin proximity to T-cell subpopulations, could not be clearly associated with a specific cell phenotype. Common pre- and post-transplant T-cell clusters were T, T-naive, T- memory, and ICOS+T; B-cell clusters were naive-B and B-cells: others included CD14+monocytes and NK cells. Compared with pre- LT samples, post-transplant samples did not contain DCs as a unique cell cluster. A B-cell cluster with significantly upregulated CREM expression was termed CREM+B-cells. This cluster was uniquely present in post-transplant samples, with higher counts in R compared with NR. Differentially expressed genes (DEG) in R compared with NR were identified in each annotated PBMC cluster in post-transplant and pre-transplant samples. DEGs uniquely found in post-transplant but not pre-transplant comparisons with log fold change (logFC) > 2.5, and < -2.5 served as a suggestive gene set for corroboration in biopsy regions of interest (ROIs). DEGs that remained significant after FDR correction (p-adj < 0.05) were used for enrichment analysis.

[0158] Common transcriptional changes in functionally distinct PBMC subsets from rejectors: The proportions of up- and down-regulated DEGs in memory, ICOS+ and naive T-cell clusters was 1 1 : 5, 12: 4 and 3: 7, respectively, in post-transplant samples. Five significantly upregulated genes in memory T-cells, SELL, IL-32, JUNB, ACTB and DDX3Ygenes were enriched for the transcription factor (TF) GCMb:Max; motif: ATGCGGGYNNCAYGTG (SEQ ID NO: 7)(p-adj 0.049, G-profiler). These and other coordinately expressed genes comprise a previously reported multicellular transcriptional program, pTNI04, in colorectal cancer-infiltrating T-cells, NK cells and innate lymphoid cells. Examples of significant DEGs and associated cell types in posttransplant samples were DDX3Y in all three T-cell subpopulations, naive and CREM+B-cells and monocytes; IL-32 in memory T-cells and NK cells; CREM, a TF unique to this pTNI04 program in ICOS-T-cells and CREM+B-cells; CD52 another pTNI04 program gene, in all three B-cell subsets. pTNI04 program genes with nominal differential expression were CREM in B-cells and NK cells; XCLI and CRTAM, with previously reported upregulation in antibody and cell-mediated kidney transplant rejection; S100A4 in NK cells; CLIC1, LDHA GAPDH and VEGFA in CD14+ monocytes.22-24 Significant DEGs in CD14+monocytes also included TMEM176A and TMEM176B (p-adj <0.025), which regulate dendritic cell differentiation.25 Of 190 total unique DEGs distributed across 8 PBMC subsets in post-transplant samples, 82 (44%) were expressed in two or more subsets, and included 52 of 102 upregulated (50%) and 30 of 88 downregulated (34%) genes.

[0159] Enhanced antigen presentation and MYC signaling in circulating CREM+B- cells. The proportions of up- to down-regulated genes were 24:16 in CREM+B, 23:19 in B-cells, and 13:23 in naive B-cells. Several significantly upregulated DEGs in CREM+B-cells (PSME1 , B2M, CD79B), and B-cells (CD79B, HLADRB1 , PSMB9) indicated upregulated antigen processing and presentation, and the related regulation of actin cytoskeleton (hsa 04612, p-adj 0.03), which is necessary for immune synapse formation.

[0160] To identify potential mechanisms of rejection, we searched for upstream regulators that drive DEG in R compared with NR in CREM+B-cells, which are uniquely present in post-transplant samples (IPA, QIAGEN Digital Insights, RRID: SCR_008653). For reference, DEGs in B-cells and naive B-cells, which were present in pre- and post-transplant samples were also analyzed. MYC emerged as the predicted regulatory TF of DEGs in each subset. However, the predicted activity pattern was MYC activation in CREM+B cells (Z score: +1 .097, p value: 6.79 E- 07), and MYC inhibition in B-cells (z score: -0.946, p value: 7.64 E-03) and naive B-cells (Z score: -0.673, p value: 2.71 E-05).

[0161] Localizing regions of interest (ROIs) in liver allografts. In biopsies from 2 NR and 5 R, Uniform Manifold Approximation and Projection (UMAP) defined six clusters, 0-5, each with unique anchor genes. All clusters except cluster 3 showed higher cell counts in R compared with NR. We evaluated clusters for their colocalization with portal and pericentral liver regions. Portal regions uniquely contain cholangiocytes lining bile ducts surrounded by fibrous connective tissue. Pericentral regions contain central veins with draining liver sinusoids flanked by hepatocytes. Lymphocyte-rich infiltrates in these regions are diagnostic of ACR.

[0162] Clusters 4 and 5 localized to portal and pericentral ROIs, respectively, which had been independently marked by the pathologist. Unique genes in cluster 4 also included the human cholangiocyte genes, KRT7 (p-adj 9.63E-72), BICC1 (p-adj 2.3E- 67), SOX9 (p-adj 3.4E- 34), EPCAM (p-adj 4.7E-29), and ITGB8 (p-adj 1.82E-24, Table S4). The GLUL gene with known upregulation in pericentral region was the most highly expressed gene in cluster 5 (Log2FC 2.45, p-adj 1.1 E-91 , Table S4).27 Gene ontology gene sets for T-cell receptor (TCR) signaling, Tcell proliferation, T-cell cytotoxicity, BCR signaling, antigen processing and presentation and Immunoglobulin production, each representing known rejection-associated processes were also upregulated most in clusters 4 and 5 from R compared with NR.

[0163] The PBMC transcriptome is also represented in allograft ROIs. In clusters 4 and 5, R vs NR comparisons identified 356 and 552 DEGs (p-adj < 0.05), respectively. Fold changes for DEGs ranged from log2FC -3.5 for TAT to log2FC 2.74 for CXCL9 gene, both in cluster 5, greatly exceeding those seen among PBMC. The distribution of upregulated vs downregulated genes was 336 vs 20 in cluster 4 portal, and 157 vs 395 in cluster 5 pericentral regions. Consistent with T-cell rich infiltrates that characterize early ACR, upregulated genes in clusters 4 and 5 were indicative of TCR signaling, IFNy signaling, and MHC class II antigen presentation (p-adj <0.012, REACTOME).

[0164] Downregulated DEGs in both regions reflected impaired metabolic or synthetic pathways among hepatocytes in both regions and were consistent with elevated liver enzymes due to hepatocyte injury during ACR. The larger number of downregulated metabolic genes in cluster 5 coincides with the larger hepatocyte content of pericentral compared with the bile-duct-rich portal, cluster 4 region.

[0165] 39 of 190 DEGs (20%) in PBMC transcriptomes demonstrated significant differential expression in ROIs and included 31 in the portal and 24 in pericentral regions. Sixteen of 39 total genes were present in both ROIs and included a) the multicellular pTNI04 program members, IL-32, JUNB, ACTB, TMSB4X and DDX3Y, and b) antigen presenting and processing genes HLA-DRB1 , HLA-DPA1 , and HLA- DRA, the proteasomal gene PSMB9, and the MHC II chaperone, CD74, which participate in antigen processing. The 15 unique DEGs in the portal region were noteworthy for upregulated VEGFA, another potentially novel target, and known risk factor for graft vascular disease and renal transplant rejection. The eight unique genes in the pericentral region included TMEM176A and TMEM176B, which regulate differentiation of dendritic cells. Unlike upregulation in circulating monocytes, both genes were downregulated in the pericentral region (log2FC -0.44, p-adj < 0.015). Inhibition of TMEM176B has been associated with enhanced inflammasome and cytotoxic activity in tumor-infiltrating CD8 cells.

[0166] Common PBMC and allograft genes demonstrate distinct NFKB-regulated subnetworks and drug targets in ROIs. Comparative upstream regulator analysis showed that the 31 and 24 DEGs in portal and pericentral regions were both regulated by NFKB; via its binding motif: GGGGATYCCC (SEQ ID NO: 8) in portal and its binding motif: AGGGGAWTCCCCT (SEQ ID NO: 9) in pericentral regions. Upstream regulator analysis implicated another master regulator, CIITA, which regulates the expressionof MHC class II molecules and is upregulated in portal (log2FC 1.18, p-adj 2.8E-08) and pericentral regions (log2FC 1.37, p-adj 6.9E-07). Differences in NFKB signaling between regions likely emanate from regulatory TFs such as STAT3 and PRKCD as additional intermediaries between NFKB and RELA in the portal but not the pericentral region.

[0167] In the portal and pericentral NFKB subnetworks, the proteasomal subunit 9 member, PSMB9 can be specifically targeted by the proteasomal inhibitor, carfilozimab, or other inhibitors such as bortezomib, which has been used to treat antibody-mediated transplant rejection, and Lenalidomide. CD74, also upregulated in both regions is inhibited by Milatuzumab, an anti-CD74 antibody, which inhibits cell- to-cell communication necessary for cell survival. Vascular endothelial growth factor A (VEGFA) which was upregulated (Iog2fc 0.63, p-adj 0.022) in the portal but not pericentral NFKB network is inactivated by anti-VEGFA antibody, bevacizumab.

[0168] Immune cell distribution patterns in ROIs. We deconvoluted and compared transcriptomes of 175 wells from five biopsies with rejection, and 75 wells from two biopsies without rejection, all of which overlapped the portal cluster 4 region. Each 55 micron diameter well is bar-coded and collects transcripts mobilized from overlying biopsy regions from an average of 5 cells with a range of 1 -10 cells. Biopsies with rejection demonstrated significantly higher transcriptional contributions from the innate immune macrophages, monocytes and neutrophils (p=3.21 E-28 to 1.36E-12) and the adaptile immune T-cells, NK or NKT cells (natural killer, natural killer T-cells), B-cells and plasma cells (p=2.28E-18 to 0.0145). We observed near-identical trends in proportions and between-group differences in these immune cells except in pericentral cluster 5 transcriptomes, where 128 wells from biopsies with rejection were compared with 72 wells from a non-rejector biopsy.

[0169] Among innate immune cells, macrophages contributed most to the rejection transcriptome in both biopsy regions, to a greater extent, mean+ / -SD 1 1 ,8+ / -6% in pericentral regions which are largely made up of pericentral hepatocytes and sinusoids, compared with 6.5+ / -4.6% in portal regions which contain connective tissue surrounding biliary epithelial cells, portal veins and hepatic arteries. Among adaptive immune cells, T-cells contributed the most to transcriptomes in rejection compared with non-rejection biopsies in portal (6.6+ / -8.7% vs 0.2+ / - 0.3, p=2.3E-18) and pericentral regions (7.8+ / -9.3 vs 0.1 + / -0.1 %, p=4.1 E-16). The remaining cells in orderof decreasing fractional contribution to the rejection transcriptomes were monocytes, neutrophils, NK or NKT-cells, plasma cells and B-cells.

[0170] Co-expressed genes indicate immune synapse between T-cells and antigen presenting cells via MHC class II peptide-receptor complexes: Genes that were co-expressed with T cells, cDC1 (classical dendritic cells type 1 ), NK (natural killer) and NKT cells (natural killer T cells), macrophages, and neutrophils identified several molecular interactions underlying formation of immune synapses in specific regions. These cell types were identified with cell-specific gene sets (www.proteinatlas.org). Interactions suggested by co-expressed genes localized macrophages, NK / NKT cells and neutrophils to the pericentral regions, and cDC1 and T-cells to both regions.

[0171] Second, we searched for cell-cell and molecular interactions among genes that were coexpressed with cDC1 T-cells or neutrophils across all biopsies. Protein-protein interactions (PPI) underlying 142 genes co-expressed with cDC1 , and k-means clustering demonstrated a cluster with the B-cell receptor complex (G0:0019815, p- adj 0.0135, CD19, CD79A, CD79B and CD22) confirming B-cell co-localization with cDC1 . A second cluster anchored by ACTB and ACTG1 as hubs and interactions with the DC / macrophage marker, CD68, and the actin stabilizer TMSB4X suggested cell cytoskeletal mobility (G0:2000520, p-adj 0.0156), a process that allows cell-cell interaction via immune synapse formation. The third cluster comprising MHC class II genes (HLA-DRB1 , -DRA, -DPA1 , -DPB1 , DQB1 , -DRB1 , DRA, and - DMA) and CD74 indicated MHC class II peptide complex (GO: 0023026, p-adj 7.3E-06) and related cellular processes such as phosphorylation of T-cell receptor components, and translocation of ZAP70 to the immune synapse (HSA202340 p-adj 0.00013, and HSA 202427, padj 8.4E-07).

[0172] The 52 common genes co-expressed with T-cells included a cluster with several interactions between TCR genes (CD3D, CD3E, CD3G and CD8A) and the abovementioned MHC class II genes. This cluster indicated TCR signaling (GO: 0050852, p-adj 6.5E-07) which can be initiated by immune synapse. The second cluster based on DEGs for several ribosomal proteins (RPL38,RPL4,RPL7,RPL27A,MACF1 ,RPL31 ,RPL17) indicated SRP-dependent cotranslational protein targeting to membrane (GO: 0006614, p-adj 9.9E-08) and translation initiation (GO: 0006413, p-adj 2.2E-07). The third regulatory cluster included the epigenetic regulator KAT6B, the inflammatory TF JAK1 , the nucleartransporter of histones and ribosomal proteins NPM1 , the transcription regulator BPTF, and the TF ETS1 , which regulates differentiation of T-follicular and T-effector cells.

[0173] The 49 genes co-expressed with neutrophils was indicative of dendritic cell chemotaxis (GO: 0002407, p-adj 0.011 , CXCR2, GPR183, CXCR4), and neutrophil degranulation (hsa 6798695, p-adj 0.0056, GRN, ADAM10, S100P, CXCR2, LAMP1, HSPA8, FCGR3B, RAB5C, FPR1).

[0174] Finally, we identified a common module comprising 9 genes co-expressed with T-cell genes and cDC1 genes in all biopsies, which captured the spectrum of mechanisms including immune synapse formation, during early ACR. This gene set was upregulated significantly in all clusters from R compared with NR biopsies with the most pronounced difference in cluster 4 portal and cluster 5 pericentral regions (p <2e-16). The 9 genes included five MHC II genes HLA-DRA, DRB1 , DPA1 , DPB1 , DQB1 , the chaperone CD74, lymphotoxin B, and the transcription factors ETS1 and TMEM2. This gene set was enriched (p-adj < 2.3E-09) for the same processes as the parent set of all genes co-expressed with cDC1 and T-cells such as translocation of ZAP70 to the immune synapse, phosphorylation of the CD3 and TCR zeta chain, IFNy and downstream TCR signaling, and MHC II antigen presentation (REACTOME) in network analysis using PPI. HLA-DRB1 , HLA-DQB1 in this 9-gene set also indicated immunoglobulin production (GO 0002381 , p-adj 0.0157), a process that had been used to screen tissue cell clusters for rejection-related B-cell processes. We could not identify a common gene set that was co-expressed with NK / NKT cells or macrophages across all biopsies.

[0175] DSA are associated with cytotoxicity in the liver lobule: UMAPs revealed six cell clusters, 0 through 5 in biopsies from 5 rejectors of which cluster 3 localized to the portal and pericentral regions, and remaining clusters localized to the hepatocyterich lobular regions. To identify the tissue niche contributing most to humoral immune mechanisms, we first searched for and found upregulation of all three gene sets for B- cell functions described above, including immunoglobulin production (G00002381 ) in clusters 2 and 4 in 2R with circulating DSA (DSA), compared with 3R without circulating DSA (no DSA). Cluster 2 is sparsely distributed predominantly in zone 1 , while cluster 4 is more widely dispersed, with concentration in the midzonal zone 2 region. We identified 118 and 89 DEGs, respectively in clusters 2 and 4 in biopsies from DSA compared with the no DSA group. We found enrichment of humoral immuneresponse (G00006959) on the basis of 1 1 genes in cluster 2 (p-adj 7.4E-05) and 9 DEGs in cluster 4 (p-adj 0.00055). In cluster 2, the humoral response gene set included upregulated cell killing genes, GNLY, CXCL10, HLA-A and LGALS3 (GO 0001906, p-adj 4.4E-08), of which LGALS3 and CXCL10 also positively regulate mononuclear migration (GO: 0071675 p-adj 0.148). The top-ranked TF motifs enriched in all cluster 2 DEGs and the humoral response DEG subset included RELA and IRF8. The nine humoral immune response genes in cluster 4 included the upregulated chemokine CXCL13 and HRG, which aid clearing of immune complexes, participate in cell killing (GO 0001906 p-adj 00017) and negatively regulate endothelial cell chemotaxis (GO: 2001027, p-adj 0.0012). The top-ranked putative TFs for cluster 4 DEGs and the humoral response DEG subset were CEBPA and ESR1 .

[0176] Our study provides an explanation for the several cell-specific immune processes associated with early ACR on the basis of upregulated IL-32, ACTB, SELL, DDX3Y and JUNB in memory T-cells. In tumor-infiltrating T-cells, NK-cells and innate lymphoid cells, these and other genes are known to be covariably and coordinately expressed in varying combinations and constitute a multi-cellular transcriptional program called pTNI04. Interestingly, memory T-cells, where these genes were found in our study, predict LT rejection more accurately than other Tcells subsets. We also found differentially expressed pTNI04 genes in B-cells and monocytes, partly explaining enhanced antigen presentation and DSA during early rejection. The TF CREM, a member of the pTNI04 program can explain the mechanistic link between simultaneously activated effector and antigen presenting function. The CREM-CREG family of TFs binds to several promoters to enhance expression of non-MHC and MHC genes. CREM was significantly upregulated in ICOS+T-cells and in CREM+B-cells, which uniquely appeared after LT with higher counts in rejectors compared with nonrejectors. CREM+B-cells also overexpressed CD79B, a component of the B-cell receptor; PSME1 , a proteasomal gene involved in antigen processing, and B2M, which binds antigen for transport to the cell surface. DEGs in CREM+B-cells also indicated activated MYC signaling which is also seen in the pTNI04 program. MYC signaling regulates B-cell fate, is also enhanced in renal transplant rejection, but was not observed in other B-cell subsets. The immunosuppressants, mTOR inhibitors and leflunomide can inhibit MYC signaling illustrating the potential for drug selection with high-dimensional transcriptional profiling. This extensive multicellular engagement of effector and antigen presenting cells also reflects the alloresponse to a nonidenticalhuman donor. In contrast, the predominant localization of pTNI04 genes to effector cells that infiltrate tumors may reflect the low immunogenicity of tumor antigens, which arise from mutations in self-antigens.

[0177] Spatial transcriptomes corroborate transcriptional changes and mechanisms suggested by PBMC transcriptomes and confirm the presence of novel drug targets. Remarkably, and unlike previous bulk transcriptomics studies, 20% of DEGs (39 of 190) in the various PBMC subsets were significantly and differentially expressed in portal and / or pericentral regions. Among concordant blood-tissue genes, a common subset in both regions included IL-32, ACTB, and DDX3Y which were identified in circulating memory T-cells, and several HLA class II and antigen presenting genes such as PSMB9 and CD74 which were also identified in circulating B-cells and are potential drug targets. The 15 unique DEGs in the portal region included upregulated VEGFA, another potential drug target. Among the eight unique pericentral DEGs, downregulation of TMEM176A and TMEM176B indicated failure to inhibit inflammasome function and CD8 cell-mediated cytotoxicity, as confirmed by upregulated cytotoxicity genes, CD8A, SRGN, NKG7 and GZMA in both biopsy regions and GZMB in pericentral regions. The granzymes, GZMA and GZMB are known cytotoxins. SRGN or serglycin is a component of the perforin-GZM proteolytic complex. NKG7 aids exocytosis of cytotoxic granules in CD4 and CD8 cells. T-cell- mediated cytotoxicity is a hallmark of early ACR. Upregulated memory T-cell genes, PTPRC, GIMAP4, TRBC1 , TRBC2 in both regions further confirmed the importance of memory T-cells in ACR.

[0178] Our study also illustrates the importance of the tissue niche in shaping injury networks, which could explain the phenotypic variants of rejection. First, DEGs shared by PBMC subsets and the two allograft regions were enriched for NFKB-regulated networks. This could explain common druggable targets, PSMB9 and CD74 in both regions, and the similarities in the composition of the multicellular inflammatory infiltrate inferred by deconvolution of transcriptomes of both regions. However, NFKB- binding motifs among DEGs in the two ROIs differed. This difference could potentially explain why the potential drug target, VEGFA was only present in the portal region, and why the transcriptional contribution of macrophages to pericentral region was twofold higher than the portal region. Pericentral rejection infiltrates are associated with treatment-resistant rejection and DSA. PSMB9 and CD74 can be targeted by proteasomal inhibitors like bortezomib, which is used to treat antibody-mediatedrejection, and the anti-CD74 antibody Milatuzumab, respectively, while VEGFA can be targeted by specific inhibitors like bevacizumab.

[0179] Second, the tissue niche also influences cell-cell interactions during early rejection. Gene sets co-expressed with the various immune cells localized cDC1 and T-cells to both ROIs, and the innate immune macrophages, NK cells and neutrophils to the pericentral ROI. Protein-protein interactions (PPI) applied to co-expressed genes revealed evidence of immune synapse between cDC1 and B-cells based on coexpression of cDC1 and B-cell receptor genes, and between T-cells and cDC1 , based on a shared set of nine genes co-expressed with either cell in all biopsies. Notably, PPI interactions between these nine genes captured enrichment of immune synapse- related processes, as well as immunoglobulin production. This nine-gene set was upregulated in biopsies with rejection, compared with biopsies from non-rejectors. Three of nine genes in this gene set, HLA-DRA, LTB and CD74 are among 20 previously reported genes that participate in immune synapse formation in liver transplant biopsies (Wood-Trageser MA, Lesniak D, Gambella A, Golnoski K, Feng S, Bucuvalas J, et al. Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts. Hepatology. 2023;77(2):355-66). In this previous report, immune synapses were absent in biopsies from liver recipients who were rejection-free without immunosuppression.

[0180] Finally, a cytotoxicity-rich lobular milieu contributes to formation of circulating DSA during acute cellular rejection. Cytotoxicity, monocyte migration, impaired endothelial function and cell-vascular wall interactions were enriched in the lobular transcriptome of biopsies with rejection, which was associated with circulating DSA. These processes are known correlates of humoral allograft injury. DSA are more likely to accompany higher grades of rejection, which was present in one of two biopsies with circulating antibody. Antibody-mediated rejection is associated with monocyterich infiltrates. Experimental and clinical liver transplant rejection has been associated with antibodies to liver sinusoidal endothelial cells (LSECs), the largest population of nonparenchymal cells in the liver lobule after hepatocytes. LSECs account for 75% of scavenging and antigen presenting function in the liver and are tolerogenic because they suppress cytotoxic T-cells and induce T-regulatory cells. Thus, injury to LSECs due to upregulated cytotoxicity genes such as GNLY, CXCL10 and CXCL13, may lead to DSA. These genes are known to potentiate the humoral response. Other contributors include putative transcription factors which regulate these genes and mayact sequentially to aid maturation of T-follicular helper cells (Tfh) and B-cells as these cells traverse the lobular zones of the liver in the sinusoids. IRF8, a putative regulator of the periportal zone 1 transcriptome is essential for class switch recombination and affinity maturation in B-cells. CEBPA, a putative regulator of the midzonal transcriptome is highly expressed in Tfh cells and facilitates affinity maturation of B- cells, which express the highest levels of ESR1 , another putative TF enriched in zone 2. These observations explain perisinusoidal deposition of complement products during antibody-mediated LT rejection. Other findings in the lobular transcriptome include upregulated CD3G, CD3D, CD8B, and CXCL10. The corresponding proteins can be targeted by therapeutic anti-CD3 (Foralumab) and anti-CXCL10 (NI-080, Eldelumab) antibodies currently in development for other immune disorders.

[0181] In sum, common transcriptional changes in several highly differentiated immune cells emerge as the basis of many non-T-cell related immune processes during early rejection which has been termed T-cell-mediated. Concordant differentially expressed genes in single leukocytes and biopsies also reveal mechanistic networks, with differential localization and drug targets in portal and pericentral regions during rejection. Donor-specific antibodies are associated with enhanced cytotoxicity in the hepatocyte-rich liver lobule. Thus, high dimensional profiling of biopsies presents a roadmap to stratify histological rejection further into mechanistic subvariants. These subvariants can be amenable to novel drug targeting. Example 2

[0182] Blocking novel targets suppresses B-cell presentation of alloantigen and downstream T-cell and B-cell alloresponses in human peripheral blood mononuclear cells: We tested the in vitro effects of antibodies which block the novel drug targets identified in our work, on T-cell function and B-cell function (FIG. 7). The drug targets were CD74, CXCL10, VEGFA, and the proteasome represented by PSMB9 (FIG. 7 (a-d)). These targets were upregulated in the spatial transcriptome of transplant biopsies with acute cellular rejection, compared with those that were rejection-free. We also tested the effect of blocking the chemokine CXCL13, (FIG. 7 (e-g)). CXCL13 is upregulated in the spatial transcriptome of transplant biopsies that were associated with donor-specific antibody production, compared with those with rejection, but without donor-specific antibody.

[0183] We tested these effects of blocking agents on the presentation of alloantigen (intact human PBMC) on responder human PBMC that were HLA-mismatched to thealloantigen. We also tested the effects of blocking agents on the B-cell and T-cell stimulated with HLA-mismatched alloantigen. We found that all five blocking agents suppressed the T- and B-cell effector response to different degrees (FIGS. 7 and 8).

[0184] Proof-of-concept using samples from human recipients with transplant rejection: Bortezomib suppresses donor-specific immune function in samples from rejectors. As proof of potential efficacy in liver transplant rejection, we performed immune function assays on residual PBMC from three children with acute cellular rejection after liver transplantation, who had yet to be treated with steroids. We added the proteasomal inhibitor, bortezomib at final concentration of 0.5 pg / ml to one aliquot of PBMC from each rejectors. Next, we added dye-labeled donor-antigenic lysate or intact donor-like cells (HLA-matched to donor as described in Ashokkumar et al, 2017). We performed the immune function assays shown in FIG. 7. All immune function assays performed on PBMC from three transplant recipients who were experiencing acute cellular rejection demonstrated inhibition of donor-specific responses with bortezomib (FIG. 8).Example 3Rejection has traditionally been classified as T-cell mediated and driven largely by cytokine signaling and cell-mediated damage by cytotoxic T-cells, or antibody- mediated, and mediated by antibodies produced by B-cells and plasma cells, which are in turn derived from B-cells which have recognized the foreign antigen, and have differentiated into antibody-secreting B-cells and plasma cells.

[0185] The aforementioned studies in Examples 1 and 2 suggest that in addition to being cytokine-mediated, acute cellular rejection may be mediated predominantly by the upregulation of (druggable) proteasome-dependent processes, chemokine signaling, drivers of MHC-class II antigen presentation, and vascular / growth factor signaling. We evaluated the expression of chemokines, CD74 which promotes presentation of antigen via the MHC class II pathway (MHC=major histocompatibility complex), and the VEGF molecules in single cells using the second generation CosMx spatial molecular imaging system (CosMxSMI, Nanostring). This system can visualize cell outlines in general and epithelial cells using protein markers specific for these cells, and panels of 1000, 6000, or >18000 genes using fluorescent in situ hybridization (FISH). For the images shown in FIGS. 9-12, we used the 1000 gene panel to visualize expression of selected chemokine targets (CXCL10, CXCL13), CD74 which presents antigen via the MHC class II pathway, and the vascular / growthfactors, VEGF. We evaluate a normal liver biopsy and a liver biopsy with transplant rejection that was associated with circulating donor-specific anti-HLA antibody (DSA). This 1000-gene panel does not include proteasomal genes.

[0186] Initially, however, we evaluated the expression of memory markers in cells that make up the liver (FIG. 9). These memory markers have been used to identify memory T-cells. Memory T-cells respond rapidly to a foreign antigen, proliferate, and can then differentiate into cytotoxic T-cells. Cytotoxic T-cells damage the transplant organ directly by secreting granzyme and granulysin. These cytotoxins are also produced by NK and NKT cells.

[0187] Next, we visualized expression of the chemokines such as CXCL10 and CXCL13 (FIG. 10), CD74 (FIG. 11 ), and the VEGF genes (FIG. 12) in allograft biopsies with rejection. For comparison, we include biopsies from a normal uninflamed liver biopsy.

[0188] The present invention has been described with reference to certain exemplary embodiments, dispersible compositions and uses thereof. However, it will be recognized by those of ordinary skill in the art that various substitutions, modifications or combinations of any of the exemplary embodiments may be made without departing from the spirit and scope of the invention. Thus, the invention is not limited by the description of the exemplary embodiments, but rather by the appended claims as originally filed.

Claims

We claim:1 . A method of treating acute graft rejection in a patient comprising, administering to the patient one or more therapeutic agents for lowering expression of a gene selected from one or more of a proteasomal component gene, an immune synapse gene, a CD3 complex gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

2. The method of claim 1 , wherein the gene is a proteasomal component gene.

3. The method of claim 1 , wherein the gene is PSMB9 or PSME 1.

4. The method of claim 2 or 3, wherein the therapeutic agent is selected from bortezomib, carfilzomib, ixazomib, and an RNAi agent targeting a transcript of the proteasomal component gene.

5. The method of claim 1 , wherein the gene is a CD74 gene.

6. The method of claim 5, wherein the therapeutic agent is Milatuzumab, an RNAi reagent targeting a transcript of the CD74 gene.

7. The method of claim 1 , wherein the gene is a chemokine gene.

8. The method of claim 7, wherein the gene is CXCLIO ox CXCL13.

9. The method of claim 7 or 8, wherein the therapeutic agent is selected from, atorvastatin, atropine, eldelumab, methylprednisolone, NI-0801 , oxaliplatin, regramostim, ritonavir, stavudine, testosterone, zidovudine, MDX-1100, and an RNAi agent targeting a transcript of the chemokine gene.

10. The method of claim 1 , wherein the gene is a VEGF gene.11 . The method of claim 10, wherein the gene is VEGFA.

12. The method of claim 10 or 11 , wherein the therapeutic agent is selected from, bevacizumab, aflibercept, brolucizumab, ranibizumab, docetaxel, bevacizumab, oxaliplatin, pegaptanib, sorafenib, irinotecan, capecitabine, lenalidomide, OSI-632 (e.g., 3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1 -yl)butyl)ureido) isothiazole-4-carboxamide), bevasiranib, sunitinib, cisplatin, cilostazol, domatinostat, CDC-801 (e.g., 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(1 ,3-dioxoisoindolin-2-yl) propanamide), squalamine, risuteganib, fluorouracil, muparfostat, phenytoin, gentamicin, fenofibrate, conbercept, milatuzumab, MP-0250 (e.g., a VEGF / HGF- targeting DARPin), regorafenib, sildenafil, carboplatin, zaltrap, navicixizumab, elmiron,abicipar, celecoxib, leucovorin, enalapril, temozolomide, zoledronic, pemetrexed, cetuximab, fulvestrant, panitumumab, prednisone, IFNa2a, 5-fluorouracil, dalteparin, paclitaxel, gemcitabine, etoposide, lomustine, topotecan, olaparib, gefitinib, carmustine, erlotinib, thalidomide, atezolizumab, acid, vanucizumab, chelerythrine, faricimab, entrectinib, and an RNAi agent targeting a transcript of the chemokine gene.

13. the method of claim 1 , wherein the gene is CD3 and, optionally, the therapeutic agent is foralumab.

14. The method of any one of claims 1 -13, wherein the graft is a liver allograft.

15. The method of any one of claims 1 -14, wherein the therapeutic agent is an RNAi reagent or an antisense oligonucleotide.

16. The method of any one of claims 1 -15, wherein the graft rejection is T-cell mediated.

17. The method of claim 1 , further comprising conducting single-cell or bulk sequencing of a peripheral blood mononuclear cell (PBMC) or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of the patient and / or conducting a spatial transcriptomics analysis of a graft biopsy of the patient, and determining, as compared to a reference cell or bulk sequencing of a PMBC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of a non-rejector or normal patient and / or a spatial transcriptomics analysis of a graft biopsy or normal tissue of a non-rejector patient, expression of one or more of a proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, and where one or more of the proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene are overexpressed in the patient’s sample as compared to expression in the normal or non-rejector patient, treating the patient with an amount of therapeutic agent for reducing expression of the overexpressed in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

18. A method of treating acute graft rejection in a patient comprising, conducting single-cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells,and / or memory B-cells, or a graft biopsy of the patient and / or conducting a spatial transcriptomics analysis of a graft biopsy of the patient, and determining, as compared to a reference cell or bulk sequencing of a PBMC or one or more cells of a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or a graft biopsy of a non-rejector or normal patient and / or a spatial transcriptomics analysis of a graft biopsy or normal tissue of a non-rejector patient, expression of one or more of a proteasomal component gene, an immune synapse gene a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, and where one or more of the proteasomal component gene, an immune synapse gene a chemokine gene, a chemokine receptor gene, and / or a growth factor gene are overexpressed in the patient’s sample as compared to expression in the normal or non-rejector patient, administering to the patient one or more therapeutic agents for lowering expression of a gene selected from one or more of a proteasomal component gene, an immune synapse gene, a chemokine gene, a chemokine receptor gene, and / or a growth factor gene, in an amount effective to reduce expression of the gene in a PBMC or a subpopulation thereof, e.g., CD14, NK, NKT, memory subsets of CD4, CD8, CD3, naive B-cells, and / or memory B-cells, or graft tissue of the patient.

Citation Information

Patent Citations

  • Identification of New Therapeutic Uses for Known Therapeutic Agents

    US20150133390A1

  • Biomarkers for Typing Allograft Recipients

    US20200400685A1

  • Tissue molecular signatures of kidney transplant rejections

    US20200407791A1